ID,Description,GeneRatio,BgRatio,RichFactor,FoldEnrichment,zScore,pvalue,p.adjust,qvalue,geneID,Count
R-HSA-168256,Immune System,89/206,759/3769,0.11725955204216074,2.145394425470407,8.489338510647254,7.41356318006257e-15,5.938264107230119e-12,5.610896764699988e-12,PLAUR/SLC11A1/SERPINB1/SLC2A3/DAPP1/IL4R/OAS1/ICAM1/IRAK3/NLRP1/BLNK/FKBP5/PYGL/HCK/TLR8/CRISPLD2/JAK3/ICAM2/CCL2/OAS3/OAS2/VEGFA/LMNB1/BCL6/CISH/IL1R2/IL1R1/IL1RL1/IL18RAP/CD207/NCF2/CR2/CDKN1A/MT2A/IRF1/IL1B/CD93/RAC2/LIF/SIGLEC9/TRIM22/CHI3L1/CD36/IL6/MYC/PIM1/TLR2/FGF2/GPR84/SLC2A5/FCGR2A/S100A8/PLAC8/TIFA/OSMR/FCGR1A/PIK3AP1/CD1D/FCER1G/TNFRSF13C/GBP4/S100A9/CXCR1/IFI16/CCR1/TLR3/B2M/CD300A/COL3A1/TNIP2/CD14/FPR2/FPR1/LRG1/SPSB1/ISG20/CD34/TUBB6/CXCR2/UBA7/ADGRG3/SOCS3/SFTPA2/CD300E/ISG15/CASP4/SERPINA1/FCGR3A/SIGLEC14,89
R-HSA-1280215,Cytokine Signaling in Immune system,44/206,309/3769,0.1423948220064725,2.6052722531184216,7.080615890960902,9.650209522862885e-10,3.8649089139065855e-7,3.6518424457570604e-7,IL4R/OAS1/ICAM1/IRAK3/BLNK/FKBP5/HCK/JAK3/CCL2/OAS3/OAS2/VEGFA/LMNB1/BCL6/CISH/IL1R2/IL1R1/IL1RL1/IL18RAP/CDKN1A/MT2A/IRF1/IL1B/LIF/TRIM22/CD36/IL6/MYC/PIM1/FGF2/TIFA/OSMR/FCGR1A/TNFRSF13C/GBP4/CCR1/B2M/TNIP2/FPR1/ISG20/TUBB6/UBA7/SOCS3/ISG15,44
R-HSA-168249,Innate Immune System,49/206,389/3769,0.12596401028277635,2.30465220755235,6.532694516121892,6.613153085231057e-9,1.765711873756692e-6,1.6683709011512737e-6,PLAUR/SLC11A1/SERPINB1/SLC2A3/IRAK3/NLRP1/PYGL/HCK/TLR8/CRISPLD2/ICAM2/NCF2/CR2/IL1B/CD93/RAC2/SIGLEC9/CHI3L1/CD36/TLR2/GPR84/SLC2A5/FCGR2A/S100A8/PLAC8/TIFA/FCGR1A/FCER1G/S100A9/CXCR1/IFI16/TLR3/B2M/CD300A/TNIP2/CD14/FPR2/FPR1/LRG1/CXCR2/UBA7/ADGRG3/SFTPA2/CD300E/ISG15/CASP4/SERPINA1/FCGR3A/SIGLEC14,49
R-HSA-6798695,Neutrophil degranulation,29/206,187/3769,0.15508021390374332,2.837365661180624,6.196333067948857,1.6519049298974733e-7,3.3079396221196904e-5,3.1255780120954826e-5,PLAUR/SLC11A1/SERPINB1/SLC2A3/PYGL/CRISPLD2/CD93/SIGLEC9/CHI3L1/CD36/TLR2/GPR84/SLC2A5/FCGR2A/S100A8/PLAC8/FCER1G/S100A9/CXCR1/B2M/CD300A/CD14/FPR2/FPR1/LRG1/CXCR2/ADGRG3/SERPINA1/SIGLEC14,29
R-HSA-6785807,Interleukin-4 and Interleukin-13 signaling,15/206,61/3769,0.2459016393442623,4.499045042177303,6.6240825175035605,5.263240658061952e-7,8.431711534215245e-5,7.966884280308512e-5,IL4R/ICAM1/JAK3/CCL2/VEGFA/BCL6/CDKN1A/IL1B/LIF/CD36/IL6/MYC/PIM1/FGF2/SOCS3,15
R-HSA-449147,Signaling by Interleukins,29/206,200/3769,0.145,2.6529368932038833,5.775361096288404,7.239210543377476e-7,9.66434607540893e-5,9.131565580155099e-5,IL4R/ICAM1/IRAK3/BLNK/HCK/JAK3/CCL2/VEGFA/LMNB1/BCL6/CISH/IL1R2/IL1R1/IL1RL1/IL18RAP/CDKN1A/IL1B/LIF/CD36/IL6/MYC/PIM1/FGF2/TIFA/OSMR/CCR1/TNIP2/FPR1/SOCS3,29
R-HSA-877300,Interferon gamma signaling,11/206,40/3769,0.275,5.031432038834952,6.162746347788962,5.67200897097296e-6,6.490398836784773e-4,6.132593158089561e-4,OAS1/ICAM1/OAS3/OAS2/MT2A/IRF1/TRIM22/FCGR1A/GBP4/B2M/SOCS3,11
R-HSA-1236975,Antigen processing-Cross presentation,9/206,27/3769,0.3333333333333333,6.098705501618123,6.392504827244026,7.247261526576487e-6,7.256320603484707e-4,6.856290838958544e-4,CD207/NCF2/CD36/TLR2/S100A8/FCGR1A/S100A9/B2M/CD14,9
R-HSA-6783783,Interleukin-10 signaling,9/206,29/3769,0.3103448275862069,5.678105122196183,6.080150377109485,1.406788154791615e-5,0.0012520414577645374,0.001183018343035288,ICAM1/CCL2/IL1R2/IL1R1/IL1B/LIF/IL6/CCR1/FPR1,9
R-HSA-913531,Interferon Signaling,16/206,92/3769,0.17391304347826086,3.1819333051920644,5.094126392845994,2.759495857378047e-5,0.0022103561817598152,0.002088502654162964,OAS1/ICAM1/FKBP5/OAS3/OAS2/MT2A/IRF1/TRIM22/FCGR1A/GBP4/B2M/ISG20/TUBB6/UBA7/SOCS3/ISG15,16
R-HSA-5686938,Regulation of TLR by endogenous ligand,6/206,14/3769,0.42857142857142855,7.841192787794729,6.165552816562007,5.148486429618303e-5,0.003749034209203873,0.0035423557348282873,CD36/TLR2/S100A8/S100A9/CD14/SFTPA2,6
R-HSA-1236974,ER-Phagosome pathway,6/206,15/3769,0.4,7.318446601941749,5.895083500577014,8.192398326869153e-5,0.005468425883185159,0.005166959997385019,CD36/TLR2/S100A8/S100A9/B2M/CD14,6
R-HSA-5602498,MyD88 deficiency (TLR2/4),5/206,10/3769,0.5,9.148058252427184,6.20296182558051,9.351898342000782e-5,0.005762208132263558,0.00544454648412839,CD36/TLR2/S100A8/S100A9/CD14,5
R-HSA-5661231,Metallothioneins bind metals,4/206,6/3769,0.6666666666666666,12.197411003236246,6.599442989307026,1.1927589799350772e-4,0.006824285306628549,0.006448072981754289,MT2A/MT1X/MT1A/MT1M,4
R-HSA-5603041,IRAK4 deficiency (TLR2/4),5/206,11/3769,0.45454545454545453,8.31641659311562,5.842483933574277,1.638650008762275e-4,0.008750391046790549,0.008267995482807548,CD36/TLR2/S100A8/S100A9/CD14,5
R-HSA-5260271,Diseases of Immune System,6/206,18/3769,0.3333333333333333,6.098705501618123,5.213192894268806,2.6450428450907866e-4,0.011231054355518034,0.010611903648882934,CD36/TLR2/S100A8/S100A9/TLR3/CD14,6
R-HSA-5602358,Diseases associated with the TLR signaling cascade,6/206,18/3769,0.3333333333333333,6.098705501618123,5.213192894268806,2.6450428450907866e-4,0.011231054355518034,0.010611903648882934,CD36/TLR2/S100A8/S100A9/TLR3/CD14,6
R-HSA-2029481,FCGR activation,4/206,7/3769,0.5714285714285714,10.45492371705964,6.019754773036375,2.6640453527446026e-4,0.011231054355518034,0.010611903648882934,HCK/FCGR2A/FCGR1A/FCGR3A,4
R-HSA-5660526,Response to metal ions,4/206,7/3769,0.5714285714285714,10.45492371705964,6.019754773036375,2.6640453527446026e-4,0.011231054355518034,0.010611903648882934,MT2A/MT1X/MT1A/MT1M,4
R-HSA-909733,Interferon alpha/beta signaling,7/206,26/3769,0.2692307692307692,4.925877520537714,4.8294164031346565,3.5505260665791787e-4,0.01421985689664961,0.013435938115107524,OAS1/OAS3/OAS2/IRF1/ISG20/SOCS3/ISG15,7
R-HSA-6783589,Interleukin-6 family signaling,4/206,8/3769,0.5,9.148058252427184,5.546622359794654,5.100545645834273e-4,0.019454938391967873,0.018382417640876406,LIF/IL6/OSMR/SOCS3,4
R-HSA-198933,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,11/206,65/3769,0.16923076923076924,3.096265870052278,4.098724227721085,6.54974477832702e-4,0.023847025306545193,0.022532375577115443,ICAM1/ICAM2/SIGLEC9/FCGR1A/CD1D/B2M/CD300A/COL3A1/CD34/CD300E/FCGR3A,11
R-HSA-380108,Chemokine receptors bind chemokines,6/206,22/3769,0.2727272727272727,4.9898499558693725,4.512395980008868,8.84104156966421e-4,0.030789888249134926,0.029092489192625026,CXCL12/CCL2/CXCR1/CCR1/CX3CR1/CXCR2,6
R-HSA-8983711,OAS antiviral response,3/206,5/3769,0.6,10.977669902912622,5.36748046735419,0.0014829336863881471,0.04949291178320441,0.04676444388215254,OAS1/OAS3/OAS2,3
R-HSA-9833110,RSV-host interactions,6/206,26/3769,0.23076923076923078,4.22218073188947,3.9637641263755126,0.002270304364852401,0.07274055184987092,0.06873047740332111,OAS2/TLR2/TLR3/CX3CR1/CD14/ISG15,6
R-HSA-168179,Toll Like Receptor TLR1:TLR2 Cascade,9/206,55/3769,0.16363636363636364,2.993909973521624,3.5813526453037103,0.0025801223519992442,0.07654362977597758,0.07232389750828293,IRAK3/CD36/TLR2/S100A8/TIFA/S100A9/TNIP2/CD14/SFTPA2,9
R-HSA-181438,Toll Like Receptor 2 (TLR2) Cascade,9/206,55/3769,0.16363636363636364,2.993909973521624,3.5813526453037103,0.0025801223519992442,0.07654362977597758,0.07232389750828293,IRAK3/CD36/TLR2/S100A8/TIFA/S100A9/TNIP2/CD14/SFTPA2,9
R-HSA-419812,Calcitonin-like ligand receptors,3/206,6/3769,0.5,9.148058252427184,4.802239186799932,0.002846591474782785,0.07862481970003485,0.07429035464133657,CALCA/RAMP2/ADM,3
R-HSA-9909505,Modulation of host responses by IFN-stimulated genes,3/206,6/3769,0.5,9.148058252427184,4.802239186799932,0.002846591474782785,0.07862481970003485,0.07429035464133657,FKBP5/UBA7/ISG15,3
R-HSA-6803157,Antimicrobial peptides,4/206,12/3769,0.3333333333333333,6.098705501618123,4.25315391704799,0.003031381741787036,0.08093789250571386,0.07647591131034663,SLC11A1/TLR2/S100A8/S100A9,4
R-HSA-446652,Interleukin-1 family signaling,8/206,48/3769,0.16666666666666666,3.0493527508090614,3.435489683949954,0.003947136499600541,0.10198891407032366,0.09636642251995889,IRAK3/IL1R2/IL1R1/IL1RL1/IL18RAP/IL1B/TIFA/TNIP2,8
R-HSA-375276,Peptide ligand-binding receptors,13/206,105/3769,0.12380952380952381,2.2652334720295886,3.1613220161147066,0.004252606938339593,0.10644806742531293,0.10057974962717656,EDN1/CXCL12/CCL2/EDN3/F2RL3/HCRTR2/CXCR1/CCR1/CX3CR1/FPR2/FPR1/CXCR2/ACKR1,13
R-HSA-168898,Toll-like Receptor Cascades,11/206,82/3769,0.13414634146341464,2.4543570921146105,3.2012718559940856,0.004522767813315708,0.10977990965048127,0.10372791252867605,IRAK3/TLR8/CD36/TLR2/S100A8/TIFA/S100A9/TLR3/TNIP2/CD14/SFTPA2,11
R-HSA-75158,TRAIL  signaling,3/206,7/3769,0.42857142857142855,7.841192787794729,4.3556462399885465,0.0047817316794140285,0.11159952549001742,0.10544721575310143,TNFRSF10B/TNFSF10/TNFRSF10D,3
R-HSA-9820952,Respiratory Syncytial Virus Infection Pathway,6/206,30/3769,0.2,3.6592233009708743,3.515756985990975,0.004876383760487653,0.11159952549001742,0.10544721575310143,OAS2/TLR2/TLR3/CX3CR1/CD14/ISG15,6
R-HSA-1280218,Adaptive Immune System,25/206,268/3769,0.09328358208955224,1.7067272859005944,2.886053296652299,0.005112979395762564,0.11376379155571706,0.10749216916822468,DAPP1/ICAM1/BLNK/ICAM2/CD207/NCF2/SIGLEC9/CD36/TLR2/S100A8/FCGR1A/PIK3AP1/CD1D/S100A9/B2M/CD300A/COL3A1/CD14/SPSB1/CD34/TUBB6/UBA7/SOCS3/CD300E/FCGR3A,25
R-HSA-5668599,RHO GTPases Activate NADPH Oxidases,4/206,14/3769,0.2857142857142857,5.22746185852982,3.809955394806081,0.005622577587732504,0.12172120669658747,0.11501090428391667,NCF2/RAC2/S100A8/S100A9,4
R-HSA-9020702,Interleukin-1 signaling,6/206,31/3769,0.1935483870967742,3.5411838396492326,3.4156898508457108,0.0057771003900441535,0.12177519506382543,0.11506191635572707,IRAK3/IL1R2/IL1R1/IL1B/TIFA/TNIP2,6
R-HSA-983169,Class I MHC mediated antigen processing & presentation,12/206,98/3769,0.12244897959183673,2.24034079651278,2.9911832496259696,0.00650127560162356,0.1335261988948839,0.1261651054674046,CD207/NCF2/CD36/TLR2/S100A8/FCGR1A/S100A9/B2M/CD14/SPSB1/UBA7/SOCS3,12
R-HSA-166058,MyD88:MAL(TIRAP) cascade initiated on plasma membrane,8/206,53/3769,0.1509433962264151,2.7616779629968855,3.105329935559996,0.007333549908660748,0.143272523825299,0.13537413053471317,IRAK3/CD36/TLR2/S100A8/TIFA/S100A9/TNIP2/CD14,8
R-HSA-168188,Toll Like Receptor TLR6:TLR2 Cascade,8/206,53/3769,0.1509433962264151,2.7616779629968855,3.105329935559996,0.007333549908660748,0.143272523825299,0.13537413053471317,IRAK3/CD36/TLR2/S100A8/TIFA/S100A9/TNIP2/CD14,8
R-HSA-5218859,Regulated Necrosis,5/206,24/3769,0.20833333333333334,3.811690938511327,3.3222203731318434,0.008414502370302482,0.1604765809193402,0.15162975449241817,TNFRSF10B/TNFSF10/IRF1/IL1B/CASP4,5
R-HSA-140534,Caspase activation via Death Receptors in the presence of ligand,3/206,9/3769,0.3333333333333333,6.098705501618123,3.6818696278607685,0.010577628599642843,0.1925609206434981,0.18194533404648816,TNFRSF10B/TNFSF10/CD14,3
R-HSA-6791312,TP53 Regulates Transcription of Cell Cycle Genes,3/206,9/3769,0.3333333333333333,6.098705501618123,3.6818696278607685,0.010577628599642843,0.1925609206434981,0.18194533404648816,GADD45A/CDK2/CDKN1A,3
R-HSA-166016,Toll Like Receptor 4 (TLR4) Cascade,9/206,69/3769,0.13043478260869565,2.386449978894048,2.7945316642916875,0.011860651818057998,0.21111960236143237,0.19948090426160706,IRAK3/CD36/TLR2/S100A8/TIFA/S100A9/TNIP2/CD14/SFTPA2,9
R-HSA-3000170,Syndecan interactions,4/206,18/3769,0.2222222222222222,4.065803667745415,3.134643860258531,0.014473904974692814,0.2520347366245423,0.23814045027011746,THBS1/FGF2/COL3A1/ITGB3,4
R-HSA-202733,Cell surface interactions at the vascular wall,9/206,74/3769,0.12162162162162163,2.2252033586985047,2.559163088969673,0.01828429123819659,0.3116110059956482,0.2944323717864132,ANGPT2/SELPLG/TNFRSF10B/SLC16A3/F11R/FCER1G/TNFRSF10D/THBD/ITGB3,9
R-HSA-5620971,Pyroptosis,3/206,11/3769,0.2727272727272727,4.9898499558693725,3.186072576358347,0.019159555896786532,0.31972508902762525,0.30209913793398063,IRF1/IL1B/CASP4,3
R-HSA-500792,GPCR ligand binding,21/206,240/3769,0.0875,1.6009101941747572,2.3129727138893754,0.019896645871413435,0.3252492518980033,0.30731876222440946,EDN1/CXCL12/CCL2/CALCA/EDN3/ADGRE2/F2RL3/RAMP2/HTR2B/HCRTR2/LPAR4/ADM/WNT7A/CXCR1/CCR1/CX3CR1/FPR2/FPR1/ADGRE1/CXCR2/ACKR1,21
R-HSA-444473,Formyl peptide receptors bind formyl peptides and many other ligands,2/206,5/3769,0.4,7.318446601941749,3.3990038806598295,0.02664375680166961,0.38802998542067924,0.36663849072536747,FPR2/FPR1,2
R-HSA-5656169,Termination of translesion DNA synthesis,2/206,5/3769,0.4,7.318446601941749,3.3990038806598295,0.02664375680166961,0.38802998542067924,0.36663849072536747,UBA7/ISG15,2
R-HSA-8939242,RUNX1 regulates transcription of genes involved in differentiation of keratinocytes,2/206,5/3769,0.4,7.318446601941749,3.3990038806598295,0.02664375680166961,0.38802998542067924,0.36663849072536747,RUNX1/SOCS3,2
R-HSA-9675126,Diseases of mitotic cell cycle,2/206,5/3769,0.4,7.318446601941749,3.3990038806598295,0.02664375680166961,0.38802998542067924,0.36663849072536747,CDK2/CDKN1A,2
R-HSA-9687139,Aberrant regulation of mitotic cell cycle due to RB1 defects,2/206,5/3769,0.4,7.318446601941749,3.3990038806598295,0.02664375680166961,0.38802998542067924,0.36663849072536747,CDK2/CDKN1A,2
R-HSA-9702518,STAT5 activation downstream of FLT3 ITD mutants,2/206,5/3769,0.4,7.318446601941749,3.3990038806598295,0.02664375680166961,0.38802998542067924,0.36663849072536747,CDKN1A/PIM1,2
R-HSA-1169410,Antiviral mechanism by IFN-stimulated genes,6/206,43/3769,0.13953488372093023,2.552946489049447,2.462353718820622,0.02778169679766571,0.3973774845523256,0.3754706766451437,OAS1/OAS3/OAS2/TUBB6/UBA7/ISG15,6
R-HSA-9664323,FCGR3A-mediated IL10 synthesis,4/206,22/3769,0.18181818181818182,3.326566637246249,2.631274373034703,0.02917681257166897,0.40094044040981225,0.378837212240824,HCK/FCGR2A/FCGR1A/FCGR3A,4
R-HSA-109582,Hemostasis,24/206,296/3769,0.08108108108108109,1.4834689057990031,2.083258477051996,0.030446098613008517,0.40094044040981225,0.378837212240824,PLAUR/ANGPT2/SELPLG/VEGFA/F3/TNFRSF10B/SRGN/CDK2/IRF1/F2RL3/RAC2/CD36/THBS1/SLC16A3/F11R/FCER1G/PDPN/KLKB1/TNFRSF10D/TUBB6/THBD/MAFF/SERPINA1/ITGB3,24
R-HSA-5357769,Caspase activation via extrinsic apoptotic signalling pathway,3/206,13/3769,0.23076923076923078,4.22218073188947,2.797949854750966,0.03063830555844694,0.40094044040981225,0.378837212240824,TNFRSF10B/TNFSF10/CD14,3
R-HSA-5357801,Programmed Cell Death,8/206,69/3769,0.11594202898550725,2.121288870128043,2.2600723431004677,0.032862944288105114,0.40094044040981225,0.378837212240824,TJP1/LMNB1/TNFRSF10B/TNFSF10/IRF1/IL1B/CD14/CASP4,8
R-HSA-5633008,TP53 Regulates Transcription of Cell Death Genes,4/206,23/3769,0.17391304347826086,3.1819333051920644,2.5234961646403207,0.033853076040543384,0.40094044040981225,0.378837212240824,BCL6/TP53I3/TNFRSF10B/TNFRSF10D,4
R-HSA-1643685,Disease,44/206,622/3769,0.0707395498392283,1.2942590453594731,1.9308911350380114,0.03631048705145953,0.40094044040981225,0.378837212240824,SLC12A1/FGF20/BLNK/HCK/TLR8/TJP1/JAK3/OAS2/VEGFA/LMNB1/IL1R1/NR4A1/CDK2/CDKN1A/IL1B/RAC2/CHSY1/CD36/IL6/MYC/PIM1/TLR2/THBS1/FGF2/BCL2A1/FCGR2A/S100A8/FCGR1A/PIK3AP1/RUNX1/VPS28/S100A9/ADAMTS9/TLR3/KLKB1/B2M/CX3CR1/CD14/TUBB6/SFTPA2/ISG15/FCGR3A/ITGB3/H4C2,44
R-HSA-2029485,Role of phospholipids in phagocytosis,3/206,14/3769,0.21428571428571427,3.9205963938973647,2.6321566839281187,0.03746077682318726,0.40094044040981225,0.378837212240824,FCGR2A/FCGR1A/FCGR3A,3
R-HSA-69202,Cyclin E associated events during G1/S transition,3/206,14/3769,0.21428571428571427,3.9205963938973647,2.6321566839281187,0.03746077682318726,0.40094044040981225,0.378837212240824,CDK2/CDKN1A/MYC,3
R-HSA-8864260,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,3/206,14/3769,0.21428571428571427,3.9205963938973647,2.6321566839281187,0.03746077682318726,0.40094044040981225,0.378837212240824,VEGFA/CDKN1A/MYC,3
R-HSA-110313,Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template,2/206,6/3769,0.3333333333333333,6.098705501618123,3.0050353842928383,0.03854233946511304,0.40094044040981225,0.378837212240824,UBA7/ISG15,2
R-HSA-1236978,Cross-presentation of soluble exogenous antigens (endosomes),2/206,6/3769,0.3333333333333333,6.098705501618123,3.0050353842928383,0.03854233946511304,0.40094044040981225,0.378837212240824,CD207/FCGR1A,2
R-HSA-1839122,Signaling by activated point mutants of FGFR1,2/206,6/3769,0.3333333333333333,6.098705501618123,3.0050353842928383,0.03854233946511304,0.40094044040981225,0.378837212240824,FGF20/FGF2,2
R-HSA-187577,SCF(Skp2)-mediated degradation of p27/p21,2/206,6/3769,0.3333333333333333,6.098705501618123,3.0050353842928383,0.03854233946511304,0.40094044040981225,0.378837212240824,CDK2/CDKN1A,2
R-HSA-3371378,Regulation by c-FLIP,2/206,6/3769,0.3333333333333333,6.098705501618123,3.0050353842928383,0.03854233946511304,0.40094044040981225,0.378837212240824,TNFRSF10B/TNFSF10,2
R-HSA-380994,ATF4 activates genes in response to endoplasmic reticulum  stress,2/206,6/3769,0.3333333333333333,6.098705501618123,3.0050353842928383,0.03854233946511304,0.40094044040981225,0.378837212240824,CCL2/PARN,2
R-HSA-381042,PERK regulates gene expression,2/206,6/3769,0.3333333333333333,6.098705501618123,3.0050353842928383,0.03854233946511304,0.40094044040981225,0.378837212240824,CCL2/PARN,2
R-HSA-5218900,CASP8 activity is inhibited,2/206,6/3769,0.3333333333333333,6.098705501618123,3.0050353842928383,0.03854233946511304,0.40094044040981225,0.378837212240824,TNFRSF10B/TNFSF10,2
R-HSA-6788467,IL-6-type cytokine receptor ligand interactions,2/206,6/3769,0.3333333333333333,6.098705501618123,3.0050353842928383,0.03854233946511304,0.40094044040981225,0.378837212240824,LIF/OSMR,2
R-HSA-69416,Dimerization of procaspase-8,2/206,6/3769,0.3333333333333333,6.098705501618123,3.0050353842928383,0.03854233946511304,0.40094044040981225,0.378837212240824,TNFRSF10B/TNFSF10,2
R-HSA-73893,DNA Damage Bypass,2/206,6/3769,0.3333333333333333,6.098705501618123,3.0050353842928383,0.03854233946511304,0.40094044040981225,0.378837212240824,UBA7/ISG15,2
R-HSA-9762292,Regulation of CDH11 function,2/206,6/3769,0.3333333333333333,6.098705501618123,3.0050353842928383,0.03854233946511304,0.40094044040981225,0.378837212240824,ADAM33/ANGPTL4,2
R-HSA-8878159,Transcriptional regulation by RUNX3,5/206,35/3769,0.14285714285714285,2.61373092926491,2.3059991046827655,0.039567254774351066,0.4061048067419387,0.38371687502129437,SPP1/CDKN1A/MYC/RUNX1/TEAD4,5
R-HSA-216083,Integrin cell surface interactions,7/206,59/3769,0.11864406779661017,2.17072568701662,2.1790908868523866,0.04005278368615875,0.4061048067419387,0.38371687502129437,ICAM1/ICAM2/SPP1/THBS1/F11R/COL3A1/ITGB3,7
R-HSA-8953897,Cellular responses to stimuli,22/206,276/3769,0.07971014492753623,1.4583860982130292,1.9018130900775319,0.044137880730846964,0.4342930493208138,0.41035114325732974,FKBP5/CCL2/VEGFA/LMNB1/NCF2/ABCG2/SPP1/CDK2/CDKN1A/MT2A/RAMP2/HSPA12B/IL6/MYC/PARN/ADM/TUBB6/MT1X/MT1A/MT1M/ITGB3/H4C2,22
R-HSA-114604,GPVI-mediated activation cascade,3/206,15/3769,0.2,3.6592233009708743,2.4810439010572285,0.04499002340669824,0.4342930493208138,0.41035114325732974,RAC2/FCER1G/PDPN,3
R-HSA-9616222,Transcriptional regulation of granulopoiesis,5/206,37/3769,0.13513513513513514,2.472448176331672,2.1639698673249934,0.048687958899996456,0.4342930493208138,0.41035114325732974,CDK2/CDKN1A/MYC/RUNX1/H4C2,5
R-HSA-1236973,Cross-presentation of particulate exogenous antigens (phagosomes),2/206,7/3769,0.2857142857142857,5.22746185852982,2.6915377069407174,0.05204658257939269,0.4342930493208138,0.41035114325732974,NCF2/CD36,2
R-HSA-1679131,Trafficking and processing of endosomal TLR,2/206,7/3769,0.2857142857142857,5.22746185852982,2.6915377069407174,0.05204658257939269,0.4342930493208138,0.41035114325732974,TLR8/TLR3,2
R-HSA-190322,FGFR4 ligand binding and activation,2/206,7/3769,0.2857142857142857,5.22746185852982,2.6915377069407174,0.05204658257939269,0.4342930493208138,0.41035114325732974,FGF20/FGF2,2
R-HSA-190373,FGFR1c ligand binding and activation,2/206,7/3769,0.2857142857142857,5.22746185852982,2.6915377069407174,0.05204658257939269,0.4342930493208138,0.41035114325732974,FGF20/FGF2,2
R-HSA-190375,FGFR2c ligand binding and activation,2/206,7/3769,0.2857142857142857,5.22746185852982,2.6915377069407174,0.05204658257939269,0.4342930493208138,0.41035114325732974,FGF20/FGF2,2
R-HSA-2995383,Initiation of Nuclear Envelope (NE) Reformation,2/206,7/3769,0.2857142857142857,5.22746185852982,2.6915377069407174,0.05204658257939269,0.4342930493208138,0.41035114325732974,LMNB1/CCNB2,2
R-HSA-5654228,Phospholipase C-mediated cascade; FGFR4,2/206,7/3769,0.2857142857142857,5.22746185852982,2.6915377069407174,0.05204658257939269,0.4342930493208138,0.41035114325732974,FGF20/FGF2,2
R-HSA-6803205,TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain,2/206,7/3769,0.2857142857142857,5.22746185852982,2.6915377069407174,0.05204658257939269,0.4342930493208138,0.41035114325732974,BCL6/TP53I3,2
R-HSA-69563,p53-Dependent G1 DNA Damage Response,2/206,7/3769,0.2857142857142857,5.22746185852982,2.6915377069407174,0.05204658257939269,0.4342930493208138,0.41035114325732974,CDK2/CDKN1A,2
R-HSA-69580,p53-Dependent G1/S DNA damage checkpoint,2/206,7/3769,0.2857142857142857,5.22746185852982,2.6915377069407174,0.05204658257939269,0.4342930493208138,0.41035114325732974,CDK2/CDKN1A,2
R-HSA-8964058,HDL remodeling,2/206,7/3769,0.2857142857142857,5.22746185852982,2.6915377069407174,0.05204658257939269,0.4342930493208138,0.41035114325732974,LIPG/LCAT,2
R-HSA-9617828,FOXO-mediated transcription of cell cycle genes,2/206,7/3769,0.2857142857142857,5.22746185852982,2.6915377069407174,0.05204658257939269,0.4342930493208138,0.41035114325732974,GADD45A/CDKN1A,2
R-HSA-9705462,Inactivation of CSF3 (G-CSF) signaling,2/206,7/3769,0.2857142857142857,5.22746185852982,2.6915377069407174,0.05204658257939269,0.4342930493208138,0.41035114325732974,HCK/SOCS3,2
R-HSA-425407,SLC-mediated transmembrane transport,11/206,117/3769,0.09401709401709402,1.7201477055845988,1.90252456877974,0.05297242293068249,0.4342930493208138,0.41035114325732974,SLC7A2/SLC38A5/SLC11A1/SLC2A3/SLC12A1/SLC39A14/SLC1A5/SLC16A3/RUNX1/SLC13A4/SLC4A5,11
R-HSA-69656,Cyclin A:Cdk2-associated events at S phase entry,3/206,16/3769,0.1875,3.4305218446601944,2.342347815172921,0.053207828399745916,0.4342930493208138,0.41035114325732974,CDK2/CDKN1A/MYC,3
R-HSA-983695,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,3/206,16/3769,0.1875,3.4305218446601944,2.342347815172921,0.053207828399745916,0.4342930493208138,0.41035114325732974,DAPP1/BLNK/PIK3AP1,3
R-HSA-425366,"Transport of bile salts and organic acids, metal ions and amine compounds",5/206,38/3769,0.13157894736842105,2.4073837506387323,2.0963937308736766,0.05367666901717923,0.4342930493208138,0.41035114325732974,SLC11A1/SLC39A14/SLC16A3/RUNX1/SLC13A4,5
R-HSA-2559586,DNA Damage/Telomere Stress Induced Senescence,4/206,27/3769,0.14814814814814814,2.7105357784969435,2.1445851731866306,0.05667980641784659,0.44951014792767446,0.424729346685062,LMNB1/CDK2/CDKN1A/H4C2,4
R-HSA-9755511,KEAP1-NFE2L2 pathway,4/206,27/3769,0.14814814814814814,2.7105357784969435,2.1445851731866306,0.05667980641784659,0.44951014792767446,0.424729346685062,CCL2/ABCG2/CDKN1A/MYC,4
R-HSA-2219528,PI3K/AKT Signaling in Cancer,6/206,52/3769,0.11538461538461539,2.111090365944735,1.9397060450335852,0.062046783042990133,0.4652915331675303,0.4396407284939277,FGF20/NR4A1/CDKN1A/RAC2/FGF2/PIK3AP1,6
R-HSA-140877,Formation of Fibrin Clot (Clotting Cascade),3/206,17/3769,0.17647058823529413,3.228726442033124,2.214271945100369,0.0620916037338616,0.4652915331675303,0.4396407284939277,F3/KLKB1/THBD,3
R-HSA-8852276,The role of GTSE1 in G2/M progression after G2 checkpoint,3/206,17/3769,0.17647058823529413,3.228726442033124,2.214271945100369,0.0620916037338616,0.4652915331675303,0.4396407284939277,CDKN1A/CCNB2/TUBB6,3
R-HSA-373076,Class A/1 (Rhodopsin-like receptors),15/206,179/3769,0.08379888268156424,1.5331941205185224,1.7572995147703598,0.062343858448134545,0.4652915331675303,0.4396407284939277,EDN1/CXCL12/CCL2/EDN3/F2RL3/HTR2B/HCRTR2/LPAR4/CXCR1/CCR1/CX3CR1/FPR2/FPR1/CXCR2/ACKR1,15
R-HSA-1839130,Signaling by activated point mutants of FGFR3,2/206,8/3769,0.25,4.574029126213592,2.432946507237899,0.06694719745641944,0.4652915331675303,0.4396407284939277,FGF20/FGF2,2
R-HSA-190239,FGFR3 ligand binding and activation,2/206,8/3769,0.25,4.574029126213592,2.432946507237899,0.06694719745641944,0.4652915331675303,0.4396407284939277,FGF20/FGF2,2
R-HSA-190372,FGFR3c ligand binding and activation,2/206,8/3769,0.25,4.574029126213592,2.432946507237899,0.06694719745641944,0.4652915331675303,0.4396407284939277,FGF20/FGF2,2
R-HSA-2033514,FGFR3 mutant receptor activation,2/206,8/3769,0.25,4.574029126213592,2.432946507237899,0.06694719745641944,0.4652915331675303,0.4396407284939277,FGF20/FGF2,2
R-HSA-2892247,"POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation",2/206,8/3769,0.25,4.574029126213592,2.432946507237899,0.06694719745641944,0.4652915331675303,0.4396407284939277,FGF2/CRIPTO,2
R-HSA-5654227,Phospholipase C-mediated cascade; FGFR3,2/206,8/3769,0.25,4.574029126213592,2.432946507237899,0.06694719745641944,0.4652915331675303,0.4396407284939277,FGF20/FGF2,2
R-HSA-5674400,Constitutive Signaling by AKT1 E17K in Cancer,2/206,8/3769,0.25,4.574029126213592,2.432946507237899,0.06694719745641944,0.4652915331675303,0.4396407284939277,NR4A1/CDKN1A,2
R-HSA-6803211,TP53 Regulates Transcription of Death Receptors and Ligands,2/206,8/3769,0.25,4.574029126213592,2.432946507237899,0.06694719745641944,0.4652915331675303,0.4396407284939277,TNFRSF10B/TNFRSF10D,2
R-HSA-69615,G1/S DNA Damage Checkpoints,2/206,8/3769,0.25,4.574029126213592,2.432946507237899,0.06694719745641944,0.4652915331675303,0.4396407284939277,CDK2/CDKN1A,2
R-HSA-982772,Growth hormone receptor signaling,2/206,8/3769,0.25,4.574029126213592,2.432946507237899,0.06694719745641944,0.4652915331675303,0.4396407284939277,CISH/SOCS3,2
R-HSA-421270,Cell-cell junction organization,5/206,41/3769,0.12195121951219512,2.2312337201041914,1.9057925447609305,0.07035950563016662,0.4652915331675303,0.4396407284939277,CDH3/CLDN16/ADAM33/F11R/ANGPTL4,5
R-HSA-9662851,Anti-inflammatory response favouring Leishmania parasite infection,5/206,41/3769,0.12195121951219512,2.2312337201041914,1.9057925447609305,0.07035950563016662,0.4652915331675303,0.4396407284939277,HCK/IL6/FCGR2A/FCGR1A/FCGR3A,5
R-HSA-9664433,Leishmania parasite growth and survival,5/206,41/3769,0.12195121951219512,2.2312337201041914,1.9057925447609305,0.07035950563016662,0.4652915331675303,0.4396407284939277,HCK/IL6/FCGR2A/FCGR1A/FCGR3A,5
R-HSA-2172127,DAP12 interactions,3/206,18/3769,0.16666666666666666,3.0493527508090614,2.0953693432533935,0.0716151434856954,0.4652915331675303,0.4396407284939277,B2M/CD300E/SIGLEC14,3
R-HSA-512988,"Interleukin-3, Interleukin-5 and GM-CSF signaling",3/206,18/3769,0.16666666666666666,3.0493527508090614,2.0953693432533935,0.0716151434856954,0.4652915331675303,0.4396407284939277,BLNK/HCK/JAK3,3
R-HSA-8963899,Plasma lipoprotein remodeling,3/206,18/3769,0.16666666666666666,3.0493527508090614,2.0953693432533935,0.0716151434856954,0.4652915331675303,0.4396407284939277,LIPG/ANGPTL4/LCAT,3
R-HSA-373080,Class B/2 (Secretin family receptors),6/206,54/3769,0.1111111111111111,2.0329018338727076,1.8380514568199278,0.07203014995352529,0.4652915331675303,0.4396407284939277,CALCA/ADGRE2/RAMP2/ADM/WNT7A/ADGRE1,6
R-HSA-453274,Mitotic G2-G2/M phases,6/206,54/3769,0.1111111111111111,2.0329018338727076,1.8380514568199278,0.07203014995352529,0.4652915331675303,0.4396407284939277,CDK11A/CDK2/CDKN1A/PLK4/CCNB2/TUBB6,6
R-HSA-69275,G2/M Transition,6/206,54/3769,0.1111111111111111,2.0329018338727076,1.8380514568199278,0.07203014995352529,0.4652915331675303,0.4396407284939277,CDK11A/CDK2/CDKN1A/PLK4/CCNB2/TUBB6,6
R-HSA-9824446,Viral Infection Pathways,18/206,229/3769,0.07860262008733625,1.4381226947047103,1.6447239115647985,0.07263875749747051,0.465469158043791,0.43980856118468464,BLNK/HCK/TLR8/TJP1/JAK3/OAS2/VEGFA/IL1R1/TLR2/RUNX1/VPS28/TLR3/B2M/CX3CR1/CD14/TUBB6/ISG15/H4C2,18
R-HSA-2995410,Nuclear Envelope (NE) Reassembly,3/206,19/3769,0.15789473684210525,2.888860500766479,1.984459306063945,0.08174929675667503,0.4820672727191508,0.4554916473947953,LMNB1/CCNB2/TUBB6,3
R-HSA-352230,Amino acid transport across the plasma membrane,3/206,19/3769,0.15789473684210525,2.888860500766479,1.984459306063945,0.08174929675667503,0.4820672727191508,0.4554916473947953,SLC7A2/SLC38A5/SLC1A5,3
R-HSA-1538133,G0 and Early G1,2/206,9/3769,0.2222222222222222,4.065803667745415,2.213873581377405,0.08305278855835557,0.4820672727191508,0.4554916473947953,CDK2/MYC,2
R-HSA-2033519,Activated point mutants of FGFR2,2/206,9/3769,0.2222222222222222,4.065803667745415,2.213873581377405,0.08305278855835557,0.4820672727191508,0.4554916473947953,FGF20/FGF2,2
R-HSA-425410,Metal ion SLC transporters,2/206,9/3769,0.2222222222222222,4.065803667745415,2.213873581377405,0.08305278855835557,0.4820672727191508,0.4554916473947953,SLC11A1/SLC39A14,2
R-HSA-5654219,Phospholipase C-mediated cascade: FGFR1,2/206,9/3769,0.2222222222222222,4.065803667745415,2.213873581377405,0.08305278855835557,0.4820672727191508,0.4554916473947953,FGF20/FGF2,2
R-HSA-5654221,Phospholipase C-mediated cascade; FGFR2,2/206,9/3769,0.2222222222222222,4.065803667745415,2.213873581377405,0.08305278855835557,0.4820672727191508,0.4554916473947953,FGF20/FGF2,2
R-HSA-5654720,PI-3K cascade:FGFR4,2/206,9/3769,0.2222222222222222,4.065803667745415,2.213873581377405,0.08305278855835557,0.4820672727191508,0.4554916473947953,FGF20/FGF2,2
R-HSA-9635486,Infection with Mycobacterium tuberculosis,2/206,9/3769,0.2222222222222222,4.065803667745415,2.213873581377405,0.08305278855835557,0.4820672727191508,0.4554916473947953,TLR2/B2M,2
R-HSA-9674555,Signaling by CSF3 (G-CSF),2/206,9/3769,0.2222222222222222,4.065803667745415,2.213873581377405,0.08305278855835557,0.4820672727191508,0.4554916473947953,HCK/SOCS3,2
R-HSA-9703465,Signaling by FLT3 fusion proteins,2/206,9/3769,0.2222222222222222,4.065803667745415,2.213873581377405,0.08305278855835557,0.4820672727191508,0.4554916473947953,CDKN1A/PIM1,2
R-HSA-9703648,Signaling by FLT3 ITD and TKD mutants,2/206,9/3769,0.2222222222222222,4.065803667745415,2.213873581377405,0.08305278855835557,0.4820672727191508,0.4554916473947953,CDKN1A/PIM1,2
R-HSA-9830364,Formation of the nephric duct,2/206,9/3769,0.2222222222222222,4.065803667745415,2.213873581377405,0.08305278855835557,0.4820672727191508,0.4554916473947953,FGF2/PLAC8,2
R-HSA-9705671,SARS-CoV-2 activates/modulates innate and adaptive immune responses,4/206,32/3769,0.125,2.287014563106796,1.757834757400334,0.09425917368128589,0.5279672288779966,0.49886120975527914,TLR8/TLR2/B2M/ISG15,4
R-HSA-9013423,RAC3 GTPase cycle,5/206,45/3769,0.1111111111111111,2.0329018338727076,1.6758749726430804,0.09653879087726774,0.5279672288779966,0.49886120975527914,SLC1A5/NCF2/ARAP3/EPHA2/VANGL1,5
R-HSA-73857,RNA Polymerase II Transcription,25/206,351/3769,0.07122507122507123,1.3031422012004537,1.433821455868396,0.09797234237053776,0.5279672288779966,0.49886120975527914,SLC2A3/FKBP5/TJP1/NAMPT/VEGFA/BCL6/TP53I3/GADD45A/SPP1/TNFRSF10B/NR4A1/CDK2/CDKN1A/IL6/MYC/THBS1/RUNX1/TNFRSF10D/NABP1/SOCS3/ZNF799/TEAD4/ZNF442/ZIM2/H4C2,25
R-HSA-190241,FGFR2 ligand binding and activation,2/206,10/3769,0.2,3.6592233009708743,2.0244161382502255,0.10018853781455118,0.5279672288779966,0.49886120975527914,FGF20/FGF2,2
R-HSA-190242,FGFR1 ligand binding and activation,2/206,10/3769,0.2,3.6592233009708743,2.0244161382502255,0.10018853781455118,0.5279672288779966,0.49886120975527914,FGF20/FGF2,2
R-HSA-452723,Transcriptional regulation of pluripotent stem cells,2/206,10/3769,0.2,3.6592233009708743,2.0244161382502255,0.10018853781455118,0.5279672288779966,0.49886120975527914,FGF2/CRIPTO,2
R-HSA-5654710,PI-3K cascade:FGFR3,2/206,10/3769,0.2,3.6592233009708743,2.0244161382502255,0.10018853781455118,0.5279672288779966,0.49886120975527914,FGF20/FGF2,2
R-HSA-5654712,FRS-mediated FGFR4 signaling,2/206,10/3769,0.2,3.6592233009708743,2.0244161382502255,0.10018853781455118,0.5279672288779966,0.49886120975527914,FGF20/FGF2,2
R-HSA-5654719,SHC-mediated cascade:FGFR4,2/206,10/3769,0.2,3.6592233009708743,2.0244161382502255,0.10018853781455118,0.5279672288779966,0.49886120975527914,FGF20/FGF2,2
R-HSA-5654733,Negative regulation of FGFR4 signaling,2/206,10/3769,0.2,3.6592233009708743,2.0244161382502255,0.10018853781455118,0.5279672288779966,0.49886120975527914,FGF20/FGF2,2
R-HSA-9022699,MECP2 regulates neuronal receptors and channels,2/206,10/3769,0.2,3.6592233009708743,2.0244161382502255,0.10018853781455118,0.5279672288779966,0.49886120975527914,SLC2A3/FKBP5,2
R-HSA-912631,Regulation of signaling by CBL,2/206,10/3769,0.2,3.6592233009708743,2.0244161382502255,0.10018853781455118,0.5279672288779966,0.49886120975527914,BLNK/HCK,2
R-HSA-9682385,FLT3 signaling in disease,2/206,10/3769,0.2,3.6592233009708743,2.0244161382502255,0.10018853781455118,0.5279672288779966,0.49886120975527914,CDKN1A/PIM1,2
R-HSA-9825892,Regulation of MITF-M-dependent genes involved in cell cycle and proliferation,2/206,10/3769,0.2,3.6592233009708743,2.0244161382502255,0.10018853781455118,0.5279672288779966,0.49886120975527914,CDK2/CDKN1A,2
R-HSA-212436,Generic Transcription Pathway,24/206,337/3769,0.0712166172106825,1.3029875255682637,1.401351895382639,0.10376030904328891,0.5432157355795714,0.5132690897978998,SLC2A3/FKBP5/TJP1/NAMPT/VEGFA/BCL6/TP53I3/GADD45A/SPP1/TNFRSF10B/NR4A1/CDK2/CDKN1A/IL6/MYC/THBS1/RUNX1/TNFRSF10D/SOCS3/ZNF799/TEAD4/ZNF442/ZIM2/H4C2,24
R-HSA-5663205,Infectious disease,23/206,322/3769,0.07142857142857142,1.306865464632455,1.3843198770922658,0.1071672798903478,0.5574090337153804,0.5266799332956943,BLNK/HCK/TLR8/TJP1/JAK3/OAS2/VEGFA/IL1R1/IL1B/IL6/TLR2/FCGR2A/FCGR1A/RUNX1/VPS28/TLR3/B2M/CX3CR1/CD14/TUBB6/ISG15/FCGR3A/H4C2,23
R-HSA-9759194,Nuclear events mediated by NFE2L2,3/206,22/3769,0.13636363636363635,2.4949249779346863,1.6907135695476208,0.11549188261044903,0.59171360981761,0.5590933510202531,CCL2/ABCG2/MYC,3
R-HSA-5654689,PI-3K cascade:FGFR1,2/206,11/3769,0.18181818181818182,3.326566637246249,1.857866897750382,0.1181949782407211,0.59171360981761,0.5590933510202531,FGF20/FGF2,2
R-HSA-5654695,PI-3K cascade:FGFR2,2/206,11/3769,0.18181818181818182,3.326566637246249,1.857866897750382,0.1181949782407211,0.59171360981761,0.5590933510202531,FGF20/FGF2,2
R-HSA-5654704,SHC-mediated cascade:FGFR3,2/206,11/3769,0.18181818181818182,3.326566637246249,1.857866897750382,0.1181949782407211,0.59171360981761,0.5590933510202531,FGF20/FGF2,2
R-HSA-5654706,FRS-mediated FGFR3 signaling,2/206,11/3769,0.18181818181818182,3.326566637246249,1.857866897750382,0.1181949782407211,0.59171360981761,0.5590933510202531,FGF20/FGF2,2
R-HSA-5654732,Negative regulation of FGFR3 signaling,2/206,11/3769,0.18181818181818182,3.326566637246249,1.857866897750382,0.1181949782407211,0.59171360981761,0.5590933510202531,FGF20/FGF2,2
R-HSA-3000171,Non-integrin membrane-ECM interactions,5/206,48/3769,0.10416666666666667,1.9058454692556634,1.5185393357254116,0.11898445550012421,0.5919661419602453,0.5593319614553076,ACTA2/THBS1/FGF2/COL3A1/ITGB3,5
R-HSA-114608,Platelet degranulation,6/206,62/3769,0.0967741935483871,1.7705919198246163,1.4709237105626205,0.12053495743154433,0.5957636135579105,0.5629200843000692,VEGFA/SRGN/CD36/THBS1/SERPINA1/ITGB3,6
R-HSA-2029480,Fcgamma receptor (FCGR) dependent phagocytosis,4/206,35/3769,0.11428571428571428,2.0909847434119277,1.5590020590833378,0.12123529214724023,0.5957636135579105,0.5629200843000692,HCK/FCGR2A/FCGR1A/FCGR3A,4
R-HSA-1474244,Extracellular matrix organization,13/206,167/3769,0.07784431137724551,1.4242485901982445,1.348304348550123,0.12253332143328714,0.59847067358575,0.5654779082832699,ICAM1/ASPN/ACTA2/ICAM2/SPP1/THBS1/FGF2/PLOD2/F11R/ADAMTS9/KLKB1/COL3A1/ITGB3,13
R-HSA-9679506,SARS-CoV Infections,10/206,123/3769,0.08130081300813008,1.4874891467361275,1.321570454409234,0.1329250856104214,0.6093244873913272,0.5757333680719682,BLNK/TLR8/TJP1/JAK3/VEGFA/IL1R1/TLR2/RUNX1/B2M/ISG15,10
R-HSA-76005,Response to elevated platelet cytosolic Ca2+,6/206,64/3769,0.09375,1.7152609223300972,1.3875272633865228,0.13470015874186037,0.6093244873913272,0.5757333680719682,VEGFA/SRGN/CD36/THBS1/SERPINA1/ITGB3,6
R-HSA-164952,The role of Nef in HIV-1 replication and disease pathogenesis,2/206,12/3769,0.16666666666666666,3.0493527508090614,1.709495219276826,0.13692685109917463,0.6093244873913272,0.5757333680719682,HCK/B2M,2
R-HSA-1839126,FGFR2 mutant receptor activation,2/206,12/3769,0.16666666666666666,3.0493527508090614,1.709495219276826,0.13692685109917463,0.6093244873913272,0.5757333680719682,FGF20/FGF2,2
R-HSA-201556,Signaling by ALK,2/206,12/3769,0.16666666666666666,3.0493527508090614,1.709495219276826,0.13692685109917463,0.6093244873913272,0.5757333680719682,JAK3/MYC,2
R-HSA-420029,Tight junction interactions,2/206,12/3769,0.16666666666666666,3.0493527508090614,1.709495219276826,0.13692685109917463,0.6093244873913272,0.5757333680719682,CLDN16/F11R,2
R-HSA-5654688,SHC-mediated cascade:FGFR1,2/206,12/3769,0.16666666666666666,3.0493527508090614,1.709495219276826,0.13692685109917463,0.6093244873913272,0.5757333680719682,FGF20/FGF2,2
R-HSA-5654693,FRS-mediated FGFR1 signaling,2/206,12/3769,0.16666666666666666,3.0493527508090614,1.709495219276826,0.13692685109917463,0.6093244873913272,0.5757333680719682,FGF20/FGF2,2
R-HSA-5654699,SHC-mediated cascade:FGFR2,2/206,12/3769,0.16666666666666666,3.0493527508090614,1.709495219276826,0.13692685109917463,0.6093244873913272,0.5757333680719682,FGF20/FGF2,2
R-HSA-5654700,FRS-mediated FGFR2 signaling,2/206,12/3769,0.16666666666666666,3.0493527508090614,1.709495219276826,0.13692685109917463,0.6093244873913272,0.5757333680719682,FGF20/FGF2,2
R-HSA-5654727,Negative regulation of FGFR2 signaling,2/206,12/3769,0.16666666666666666,3.0493527508090614,1.709495219276826,0.13692685109917463,0.6093244873913272,0.5757333680719682,FGF20/FGF2,2
R-HSA-5655332,Signaling by FGFR3 in disease,2/206,12/3769,0.16666666666666666,3.0493527508090614,1.709495219276826,0.13692685109917463,0.6093244873913272,0.5757333680719682,FGF20/FGF2,2
R-HSA-69231,Cyclin D associated events in G1,2/206,12/3769,0.16666666666666666,3.0493527508090614,1.709495219276826,0.13692685109917463,0.6093244873913272,0.5757333680719682,CDK2/CDKN1A,2
R-HSA-69236,G1 Phase,2/206,12/3769,0.16666666666666666,3.0493527508090614,1.709495219276826,0.13692685109917463,0.6093244873913272,0.5757333680719682,CDK2/CDKN1A,2
R-HSA-9759475,Regulation of CDH11 Expression and Function,2/206,12/3769,0.16666666666666666,3.0493527508090614,1.709495219276826,0.13692685109917463,0.6093244873913272,0.5757333680719682,ADAM33/ANGPTL4,2
R-HSA-9856532,Mechanical load activates signaling by PIEZO1 and integrins in osteocytes,2/206,12/3769,0.16666666666666666,3.0493527508090614,1.709495219276826,0.13692685109917463,0.6093244873913272,0.5757333680719682,SPP1/ITGB3,2
R-HSA-74160,Gene expression (Transcription),27/206,399/3769,0.06766917293233082,1.2380830717570626,1.2091527297570335,0.13803473632979762,0.6108609049733033,0.5771850853220383,SLC2A3/FKBP5/TJP1/NAMPT/VEGFA/BCL6/TP53I3/GADD45A/SPP1/TNFRSF10B/NR4A1/CDK2/CDKN1A/CD36/IL6/MYC/THBS1/RUNX1/ANGPTL4/TNFRSF10D/NABP1/SOCS3/ZNF799/TEAD4/ZNF442/ZIM2/H4C2,27
R-HSA-1222556,ROS and RNS production in phagocytes,3/206,24/3769,0.125,2.287014563106796,1.5207027001106337,0.1404229768561269,0.6131812289592012,0.5793774934248843,SLC11A1/NCF2/RAC2,3
R-HSA-2029482,Regulation of actin dynamics for phagocytic cup formation,3/206,24/3769,0.125,2.287014563106796,1.5207027001106337,0.1404229768561269,0.6131812289592012,0.5793774934248843,FCGR2A/FCGR1A/FCGR3A,3
R-HSA-9679191,Potential therapeutics for SARS,4/206,37/3769,0.10810810810810811,1.9779585410653373,1.4372477404473403,0.14085561314418604,0.6131812289592012,0.5793774934248843,BLNK/JAK3/VEGFA/IL1R1,4
R-HSA-76002,"Platelet activation, signaling and aggregation",10/206,125/3769,0.08,1.4636893203883494,1.267576157836075,0.1433205520522323,0.6186403026942694,0.5845356168436556,VEGFA/SRGN/F2RL3/RAC2/CD36/THBS1/FCER1G/PDPN/SERPINA1/ITGB3,10
R-HSA-9711123,Cellular response to chemical stress,5/206,51/3769,0.09803921568627451,1.7937369122406244,1.37210743857156,0.14365430249829475,0.6186403026942694,0.5845356168436556,CCL2/NCF2/ABCG2/CDKN1A/MYC,5
R-HSA-2559582,Senescence-Associated Secretory Phenotype (SASP),4/206,38/3769,0.10526315789473684,1.925907000510986,1.3792013943335217,0.15111195951206924,0.6353192131938508,0.6002950447287978,CDK2/CDKN1A/IL6/H4C2,4
R-HSA-9614085,FOXO-mediated transcription,3/206,25/3769,0.12,2.1955339805825242,1.4419332448272262,0.15351133356570787,0.6353192131938508,0.6002950447287978,BCL6/GADD45A/CDKN1A,3
R-HSA-1839124,FGFR1 mutant receptor activation,2/206,13/3769,0.15384615384615385,2.81478715459298,1.5758530877378256,0.1562520411974889,0.6353192131938508,0.6002950447287978,FGF20/FGF2,2
R-HSA-450531,Regulation of mRNA stability by proteins that bind AU-rich elements,2/206,13/3769,0.15384615384615385,2.81478715459298,1.5758530877378256,0.1562520411974889,0.6353192131938508,0.6002950447287978,ZFP36/PARN,2
R-HSA-5213460,RIPK1-mediated regulated necrosis,2/206,13/3769,0.15384615384615385,2.81478715459298,1.5758530877378256,0.1562520411974889,0.6353192131938508,0.6002950447287978,TNFRSF10B/TNFSF10,2
R-HSA-5654716,Downstream signaling of activated FGFR4,2/206,13/3769,0.15384615384615385,2.81478715459298,1.5758530877378256,0.1562520411974889,0.6353192131938508,0.6002950447287978,FGF20/FGF2,2
R-HSA-5654726,Negative regulation of FGFR1 signaling,2/206,13/3769,0.15384615384615385,2.81478715459298,1.5758530877378256,0.1562520411974889,0.6353192131938508,0.6002950447287978,FGF20/FGF2,2
R-HSA-5675482,Regulation of necroptotic cell death,2/206,13/3769,0.15384615384615385,2.81478715459298,1.5758530877378256,0.1562520411974889,0.6353192131938508,0.6002950447287978,TNFRSF10B/TNFSF10,2
R-HSA-9013424,RHOV GTPase cycle,2/206,13/3769,0.15384615384615385,2.81478715459298,1.5758530877378256,0.1562520411974889,0.6353192131938508,0.6002950447287978,EPHA2/VANGL1,2
R-HSA-936440,Negative regulators of DDX58/IFIH1 signaling,2/206,13/3769,0.15384615384615385,2.81478715459298,1.5758530877378256,0.1562520411974889,0.6353192131938508,0.6002950447287978,UBA7/ISG15,2
R-HSA-9820960,Respiratory syncytial virus (RSV) attachment and entry,2/206,13/3769,0.15384615384615385,2.81478715459298,1.5758530877378256,0.1562520411974889,0.6353192131938508,0.6002950447287978,CX3CR1/CD14,2
R-HSA-174824,"Plasma lipoprotein assembly, remodeling, and clearance",4/206,39/3769,0.10256410256410256,1.8765247697286531,1.3228884570804096,0.16164453645908353,0.6539256247662926,0.6178757135251518,LIPG/LSR/ANGPTL4/LCAT,4
R-HSA-9705683,SARS-CoV-2-host interactions,5/206,54/3769,0.09259259259259259,1.6940848615605897,1.235125787476646,0.17033476441590217,0.6856188256137571,0.6478217170856052,TLR8/TJP1/TLR2/B2M/ISG15,5
R-HSA-111465,Apoptotic cleavage of cellular proteins,2/206,14/3769,0.14285714285714285,2.61373092926491,1.454357973050156,0.17605058525987255,0.6946626541534873,0.6563669733048917,TJP1/LMNB1,2
R-HSA-5654708,Downstream signaling of activated FGFR3,2/206,14/3769,0.14285714285714285,2.61373092926491,1.454357973050156,0.17605058525987255,0.6946626541534873,0.6563669733048917,FGF20/FGF2,2
R-HSA-9759476,Regulation of Homotypic Cell-Cell Adhesion,2/206,14/3769,0.14285714285714285,2.61373092926491,1.454357973050156,0.17605058525987255,0.6946626541534873,0.6563669733048917,ADAM33/ANGPTL4,2
R-HSA-9764260,Regulation of Expression and Function of Type II Classical Cadherins,2/206,14/3769,0.14285714285714285,2.61373092926491,1.454357973050156,0.17605058525987255,0.6946626541534873,0.6563669733048917,ADAM33/ANGPTL4,2
R-HSA-446728,Cell junction organization,5/206,55/3769,0.09090909090909091,1.6632833186231244,1.1913534208072853,0.179633348944053,0.7053250612950316,0.6664415783837674,CDH3/CLDN16/ADAM33/F11R/ANGPTL4,5
R-HSA-418990,Adherens junctions interactions,3/206,27/3769,0.1111111111111111,2.0329018338727076,1.2950012423751516,0.18075227772157149,0.7062564607559939,0.6673216312288057,CDH3/ADAM33/ANGPTL4,3
R-HSA-196849,Metabolism of water-soluble vitamins and cofactors,4/206,41/3769,0.0975609756097561,1.7849869760833532,1.2150595799370103,0.18347229193128461,0.7134043972667912,0.674075513022962,SLC2A3/MTHFD2/NAMPT/ENPP1,4
R-HSA-109581,Apoptosis,5/206,56/3769,0.08928571428571429,1.6335818307905687,1.148458746078474,0.18911852960444026,0.7276259844728771,0.6875130860582149,TJP1/LMNB1/TNFRSF10B/TNFSF10/CD14,5
R-HSA-9006936,Signaling by TGFB family members,5/206,56/3769,0.08928571428571429,1.6335818307905687,1.148458746078474,0.18911852960444026,0.7276259844728771,0.6875130860582149,MYC/FGF2/F11R/INHBB/ITGB3,5
R-HSA-1500931,Cell-Cell communication,6/206,71/3769,0.08450704225352113,1.5461506905510736,1.116964458301098,0.18991589030585437,0.7276259844728771,0.6875130860582149,CDH3/CLDN16/ADAM33/F11R/ANGPTL4/SFTPA2,6
R-HSA-186797,Signaling by PDGF,3/206,28/3769,0.10714285714285714,1.9602981969486823,1.2262313666896305,0.19483327641565643,0.7276259844728771,0.6875130860582149,SPP1/THBS1/COL3A1,3
R-HSA-1266695,Interleukin-7 signaling,2/206,15/3769,0.13333333333333333,2.439482200647249,1.3430307012172997,0.19621374862189944,0.7276259844728771,0.6875130860582149,JAK3/CISH,2
R-HSA-2980766,Nuclear Envelope Breakdown,2/206,15/3769,0.13333333333333333,2.439482200647249,1.3430307012172997,0.19621374862189944,0.7276259844728771,0.6875130860582149,LMNB1/CCNB2,2
R-HSA-3928663,EPHA-mediated growth cone collapse,2/206,15/3769,0.13333333333333333,2.439482200647249,1.3430307012172997,0.19621374862189944,0.7276259844728771,0.6875130860582149,EPHA2/EFNA1,2
R-HSA-5654696,Downstream signaling of activated FGFR2,2/206,15/3769,0.13333333333333333,2.439482200647249,1.3430307012172997,0.19621374862189944,0.7276259844728771,0.6875130860582149,FGF20/FGF2,2
R-HSA-5655302,Signaling by FGFR1 in disease,2/206,15/3769,0.13333333333333333,2.439482200647249,1.3430307012172997,0.19621374862189944,0.7276259844728771,0.6875130860582149,FGF20/FGF2,2
R-HSA-69273,Cyclin A/B1/B2 associated events during G2/M transition,2/206,15/3769,0.13333333333333333,2.439482200647249,1.3430307012172997,0.19621374862189944,0.7276259844728771,0.6875130860582149,CDK2/CCNB2,2
R-HSA-6811558,"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",5/206,57/3769,0.08771929824561403,1.6049225004258219,1.106405507019572,0.1987803697649973,0.7337468948468333,0.6932965600826246,FGF20/IL1RL1/RAC2/FGF2/PIK3AP1,5
R-HSA-372790,Signaling by GPCR,24/206,367/3769,0.0653950953678474,1.1964762836961984,0.952482836443495,0.20013786649993942,0.7353689498461077,0.6948291936912431,EDN1/CXCL12/CCL2/CALCA/EDN3/ADGRE2/F2RL3/RAMP2/HTR2B/HCRTR2/GPR84/RGS16/LPAR4/ADM/WNT7A/CXCR1/CCR1/CX3CR1/FPR2/FPR1/ADGRE1/CXCR2/ARHGEF15/ACKR1,24
R-HSA-9013404,RAC2 GTPase cycle,4/206,43/3769,0.09302325581395349,1.7019643260329644,1.1130354335291237,0.20620415596891747,0.7493732352806591,0.7080614444665142,NCF2/RAC2/EPHA2/VANGL1,4
R-HSA-2559583,Cellular Senescence,5/206,58/3769,0.08620689655172414,1.5772514228322734,1.0651595799639693,0.2086087442659114,0.7493732352806591,0.7080614444665142,LMNB1/CDK2/CDKN1A/IL6/H4C2,5
R-HSA-425393,Transport of inorganic cations/anions and amino acids/oligopeptides,5/206,58/3769,0.08620689655172414,1.5772514228322734,1.0651595799639693,0.2086087442659114,0.7493732352806591,0.7080614444665142,SLC7A2/SLC38A5/SLC12A1/SLC1A5/SLC4A5,5
R-HSA-983705,Signaling by the B Cell Receptor (BCR),3/206,29/3769,0.10344827586206896,1.8927017073987278,1.1602476817234366,0.2091745678703356,0.7493732352806591,0.7080614444665142,DAPP1/BLNK/PIK3AP1,3
R-HSA-1834949,Cytosolic sensors of pathogen-associated DNA,2/206,16/3769,0.125,2.287014563106796,1.2403244828315478,0.2166431657964927,0.7493732352806591,0.7080614444665142,IFI16/TLR3,2
R-HSA-5654743,Signaling by FGFR4,2/206,16/3769,0.125,2.287014563106796,1.2403244828315478,0.2166431657964927,0.7493732352806591,0.7080614444665142,FGF20/FGF2,2
R-HSA-5655253,Signaling by FGFR2 in disease,2/206,16/3769,0.125,2.287014563106796,1.2403244828315478,0.2166431657964927,0.7493732352806591,0.7080614444665142,FGF20/FGF2,2
R-HSA-2219530,Constitutive Signaling by Aberrant PI3K in Cancer,4/206,44/3769,0.09090909090909091,1.6632833186231244,1.0640043924541602,0.21786635435210783,0.7493732352806591,0.7080614444665142,FGF20/RAC2/FGF2/PIK3AP1,4
R-HSA-1257604,PIP3 activates AKT signaling,7/206,91/3769,0.07692307692307693,1.40739357729649,0.9458236249325551,0.2277245581586724,0.7493732352806591,0.7080614444665142,FGF20/IL1RL1/NR4A1/CDKN1A/RAC2/FGF2/PIK3AP1,7
R-HSA-3700989,Transcriptional Regulation by TP53,7/206,91/3769,0.07692307692307693,1.40739357729649,0.9458236249325551,0.2277245581586724,0.7493732352806591,0.7080614444665142,BCL6/TP53I3/GADD45A/TNFRSF10B/CDK2/CDKN1A/TNFRSF10D,7
R-HSA-5654741,Signaling by FGFR3,2/206,17/3769,0.11764705882352941,2.1524842946887492,1.1450098104324267,0.23725004073817685,0.7493732352806591,0.7080614444665142,FGF20/FGF2,2
R-HSA-9013407,RHOH GTPase cycle,2/206,17/3769,0.11764705882352941,2.1524842946887492,1.1450098104324267,0.23725004073817685,0.7493732352806591,0.7080614444665142,SLC1A5/VANGL1,2
R-HSA-9013420,RHOU GTPase cycle,2/206,17/3769,0.11764705882352941,2.1524842946887492,1.1450098104324267,0.23725004073817685,0.7493732352806591,0.7080614444665142,EPHA2/VANGL1,2
R-HSA-199418,Negative regulation of the PI3K/AKT network,5/206,61/3769,0.08196721311475409,1.4996816807257678,0.9459531517069948,0.23898977246905,0.7493732352806591,0.7080614444665142,FGF20/IL1RL1/RAC2/FGF2/PIK3AP1,5
R-HSA-9658195,Leishmania infection,6/206,77/3769,0.07792207792207792,1.425671415962678,0.9073401951826934,0.24304922981339994,0.7493732352806591,0.7080614444665142,HCK/IL1B/IL6/FCGR2A/FCGR1A/FCGR3A,6
R-HSA-9824443,Parasitic Infection Pathways,6/206,77/3769,0.07792207792207792,1.425671415962678,0.9073401951826934,0.24304922981339994,0.7493732352806591,0.7080614444665142,HCK/IL1B/IL6/FCGR2A/FCGR1A/FCGR3A,6
R-HSA-1433617,Regulation of signaling by NODAL,1/206,5/3769,0.2,3.6592233009708743,1.4305272939654692,0.2451133428758211,0.7493732352806591,0.7080614444665142,CRIPTO,1
R-HSA-1606322,ZBP1(DAI) mediated induction of type I IFNs,1/206,5/3769,0.2,3.6592233009708743,1.4305272939654692,0.2451133428758211,0.7493732352806591,0.7080614444665142,TLR3,1
R-HSA-190377,FGFR2b ligand binding and activation,1/206,5/3769,0.2,3.6592233009708743,1.4305272939654692,0.2451133428758211,0.7493732352806591,0.7080614444665142,FGF2,1
R-HSA-198323,AKT phosphorylates targets in the cytosol,1/206,5/3769,0.2,3.6592233009708743,1.4305272939654692,0.2451133428758211,0.7493732352806591,0.7080614444665142,CDKN1A,1
R-HSA-199220,Vitamin B5 (pantothenate) metabolism,1/206,5/3769,0.2,3.6592233009708743,1.4305272939654692,0.2451133428758211,0.7493732352806591,0.7080614444665142,ENPP1,1
R-HSA-2142688,Synthesis of 5-eicosatetraenoic acids,1/206,5/3769,0.2,3.6592233009708743,1.4305272939654692,0.2451133428758211,0.7493732352806591,0.7080614444665142,ALOX5AP,1
R-HSA-2559584,Formation of Senescence-Associated Heterochromatin Foci (SAHF),1/206,5/3769,0.2,3.6592233009708743,1.4305272939654692,0.2451133428758211,0.7493732352806591,0.7080614444665142,LMNB1,1
R-HSA-3000471,Scavenging by Class B Receptors,1/206,5/3769,0.2,3.6592233009708743,1.4305272939654692,0.2451133428758211,0.7493732352806591,0.7080614444665142,CD36,1
R-HSA-351906,Apoptotic cleavage of cell adhesion  proteins,1/206,5/3769,0.2,3.6592233009708743,1.4305272939654692,0.2451133428758211,0.7493732352806591,0.7080614444665142,TJP1,1
R-HSA-354194,GRB2:SOS provides linkage to MAPK signaling for Integrins,1/206,5/3769,0.2,3.6592233009708743,1.4305272939654692,0.2451133428758211,0.7493732352806591,0.7080614444665142,ITGB3,1
R-HSA-389397,Orexin and neuropeptides FF and QRFP bind to their respective receptors,1/206,5/3769,0.2,3.6592233009708743,1.4305272939654692,0.2451133428758211,0.7493732352806591,0.7080614444665142,HCRTR2,1
R-HSA-429947,Deadenylation of mRNA,1/206,5/3769,0.2,3.6592233009708743,1.4305272939654692,0.2451133428758211,0.7493732352806591,0.7080614444665142,PARN,1
R-HSA-4411364,Binding of TCF/LEF:CTNNB1 to target gene promoters,1/206,5/3769,0.2,3.6592233009708743,1.4305272939654692,0.2451133428758211,0.7493732352806591,0.7080614444665142,MYC,1
R-HSA-549127,Organic cation transport,1/206,5/3769,0.2,3.6592233009708743,1.4305272939654692,0.2451133428758211,0.7493732352806591,0.7080614444665142,RUNX1,1
R-HSA-6782315,tRNA modification in the nucleus and cytosol,1/206,5/3769,0.2,3.6592233009708743,1.4305272939654692,0.2451133428758211,0.7493732352806591,0.7080614444665142,TRMT9B,1
R-HSA-75205,Dissolution of Fibrin Clot,1/206,5/3769,0.2,3.6592233009708743,1.4305272939654692,0.2451133428758211,0.7493732352806591,0.7080614444665142,PLAUR,1
R-HSA-75892,Platelet Adhesion to exposed collagen,1/206,5/3769,0.2,3.6592233009708743,1.4305272939654692,0.2451133428758211,0.7493732352806591,0.7080614444665142,FCER1G,1
R-HSA-877312,Regulation of IFNG signaling,1/206,5/3769,0.2,3.6592233009708743,1.4305272939654692,0.2451133428758211,0.7493732352806591,0.7080614444665142,SOCS3,1
R-HSA-8851708,Signaling by FGFR2 IIIa TM,1/206,5/3769,0.2,3.6592233009708743,1.4305272939654692,0.2451133428758211,0.7493732352806591,0.7080614444665142,FGF2,1
R-HSA-8866910,TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,1/206,5/3769,0.2,3.6592233009708743,1.4305272939654692,0.2451133428758211,0.7493732352806591,0.7080614444665142,VEGFA,1
R-HSA-8877330,RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs),1/206,5/3769,0.2,3.6592233009708743,1.4305272939654692,0.2451133428758211,0.7493732352806591,0.7080614444665142,RUNX1,1
R-HSA-8934593,Regulation of RUNX1 Expression and Activity,1/206,5/3769,0.2,3.6592233009708743,1.4305272939654692,0.2451133428758211,0.7493732352806591,0.7080614444665142,RUNX1,1
R-HSA-8941855,RUNX3 regulates CDKN1A transcription,1/206,5/3769,0.2,3.6592233009708743,1.4305272939654692,0.2451133428758211,0.7493732352806591,0.7080614444665142,CDKN1A,1
R-HSA-8983432,Interleukin-15 signaling,1/206,5/3769,0.2,3.6592233009708743,1.4305272939654692,0.2451133428758211,0.7493732352806591,0.7080614444665142,JAK3,1
R-HSA-917729,Endosomal Sorting Complex Required For Transport (ESCRT),1/206,5/3769,0.2,3.6592233009708743,1.4305272939654692,0.2451133428758211,0.7493732352806591,0.7080614444665142,VPS28,1
R-HSA-937041,IKK complex recruitment mediated by RIP1,1/206,5/3769,0.2,3.6592233009708743,1.4305272939654692,0.2451133428758211,0.7493732352806591,0.7080614444665142,CD14,1
R-HSA-9614657,FOXO-mediated transcription of cell death genes,1/206,5/3769,0.2,3.6592233009708743,1.4305272939654692,0.2451133428758211,0.7493732352806591,0.7080614444665142,BCL6,1
R-HSA-9796292,Formation of axial mesoderm,1/206,5/3769,0.2,3.6592233009708743,1.4305272939654692,0.2451133428758211,0.7493732352806591,0.7080614444665142,TEAD4,1
R-HSA-9013149,RAC1 GTPase cycle,7/206,94/3769,0.07446808510638298,1.3624767609997934,0.8556508174721823,0.25270086773064093,0.7622208052821526,0.7202007477467217,SLC1A5/NCF2/ARAP3/EPHA2/TAGAP/VANGL1/ARHGEF15,7
R-HSA-170834,Signaling by TGF-beta Receptor Complex,3/206,32/3769,0.09375,1.7152609223300972,0.9769201887249616,0.2534245163186373,0.7622208052821526,0.7202007477467217,MYC/F11R/ITGB3,3
R-HSA-9013406,RHOQ GTPase cycle,3/206,32/3769,0.09375,1.7152609223300972,0.9769201887249616,0.2534245163186373,0.7622208052821526,0.7202007477467217,SLC1A5/TRIP10/VANGL1,3
R-HSA-168181,Toll Like Receptor 7/8 (TLR7/8) Cascade,4/206,47/3769,0.0851063829787234,1.5571162982854783,0.9240335808348009,0.2538326200818192,0.7622208052821526,0.7202007477467217,TLR8/TIFA/TNIP2/CD14,4
R-HSA-109704,PI3K Cascade,2/206,18/3769,0.1111111111111111,2.0329018338727076,1.0560948262482561,0.25795440289473703,0.7622208052821526,0.7202007477467217,FGF20/FGF2,2
R-HSA-2173782,Binding and Uptake of Ligands by Scavenger Receptors,2/206,18/3769,0.1111111111111111,2.0329018338727076,1.0560948262482561,0.25795440289473703,0.7622208052821526,0.7202007477467217,CD36/COL3A1,2
R-HSA-5654687,Downstream signaling of activated FGFR1,2/206,18/3769,0.1111111111111111,2.0329018338727076,1.0560948262482561,0.25795440289473703,0.7622208052821526,0.7202007477467217,FGF20/FGF2,2
R-HSA-75153,Apoptotic execution phase,2/206,18/3769,0.1111111111111111,2.0329018338727076,1.0560948262482561,0.25795440289473703,0.7622208052821526,0.7202007477467217,TJP1/LMNB1,2
R-HSA-9730414,MITF-M-regulated melanocyte development,5/206,63/3769,0.07936507936507936,1.4520727384805052,0.8699755187979378,0.2598856626107884,0.7622208052821526,0.7202007477467217,EDN1/CDK2/EDN3/CDKN1A/BCL2A1,5
R-HSA-69206,G1/S Transition,3/206,33/3769,0.09090909090909091,1.6632833186231244,0.9200973021398409,0.2684764382046528,0.7622208052821526,0.7202007477467217,CDK2/CDKN1A/MYC,3
R-HSA-69242,S Phase,3/206,33/3769,0.09090909090909091,1.6632833186231244,0.9200973021398409,0.2684764382046528,0.7622208052821526,0.7202007477467217,CDK2/CDKN1A/MYC,3
R-HSA-8936459,RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function,3/206,33/3769,0.09090909090909091,1.6632833186231244,0.9200973021398409,0.2684764382046528,0.7622208052821526,0.7202007477467217,THBS1/RUNX1/H4C2,3
R-HSA-381119,Unfolded Protein Response (UPR),2/206,19/3769,0.10526315789473684,1.925907000510986,0.9727689064217148,0.27868441538156785,0.7622208052821526,0.7202007477467217,CCL2/PARN,2
R-HSA-9696264,RND3 GTPase cycle,2/206,19/3769,0.10526315789473684,1.925907000510986,0.9727689064217148,0.27868441538156785,0.7622208052821526,0.7202007477467217,EPHA2/VANGL1,2
R-HSA-1989781,PPARA activates gene expression,3/206,34/3769,0.08823529411764706,1.614363221016562,0.865168124283773,0.28362882233783543,0.7622208052821526,0.7202007477467217,G0S2/CD36/ANGPTL4,3
R-HSA-400206,Regulation of lipid metabolism by PPARalpha,3/206,34/3769,0.08823529411764706,1.614363221016562,0.865168124283773,0.28362882233783543,0.7622208052821526,0.7202007477467217,G0S2/CD36/ANGPTL4,3
R-HSA-189200,Cellular hexose transport,1/206,6/3769,0.16666666666666666,3.0493527508090614,1.2078315817857441,0.2864275435579625,0.7622208052821526,0.7202007477467217,SLC2A3,1
R-HSA-190371,FGFR3b ligand binding and activation,1/206,6/3769,0.16666666666666666,3.0493527508090614,1.2078315817857441,0.2864275435579625,0.7622208052821526,0.7202007477467217,FGF20,1
R-HSA-194313,VEGF ligand-receptor interactions,1/206,6/3769,0.16666666666666666,3.0493527508090614,1.2078315817857441,0.2864275435579625,0.7622208052821526,0.7202007477467217,VEGFA,1
R-HSA-195399,VEGF binds to VEGFR leading to receptor dimerization,1/206,6/3769,0.16666666666666666,3.0493527508090614,1.2078315817857441,0.2864275435579625,0.7622208052821526,0.7202007477467217,VEGFA,1
R-HSA-204174,Regulation of pyruvate dehydrogenase (PDH) complex,1/206,6/3769,0.16666666666666666,3.0493527508090614,1.2078315817857441,0.2864275435579625,0.7622208052821526,0.7202007477467217,PDK1,1
R-HSA-209952,Peptide hormone biosynthesis,1/206,6/3769,0.16666666666666666,3.0493527508090614,1.2078315817857441,0.2864275435579625,0.7622208052821526,0.7202007477467217,INHBB,1
R-HSA-210990,PECAM1 interactions,1/206,6/3769,0.16666666666666666,3.0493527508090614,1.2078315817857441,0.2864275435579625,0.7622208052821526,0.7202007477467217,ITGB3,1
R-HSA-2142691,Synthesis of Leukotrienes (LT) and Eoxins (EX),1/206,6/3769,0.16666666666666666,3.0493527508090614,1.2078315817857441,0.2864275435579625,0.7622208052821526,0.7202007477467217,ALOX5AP,1
R-HSA-2173791,TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition),1/206,6/3769,0.16666666666666666,3.0493527508090614,1.2078315817857441,0.2864275435579625,0.7622208052821526,0.7202007477467217,F11R,1
R-HSA-2730905,Role of LAT2/NTAL/LAB on calcium mobilization,1/206,6/3769,0.16666666666666666,3.0493527508090614,1.2078315817857441,0.2864275435579625,0.7622208052821526,0.7202007477467217,FCER1G,1
R-HSA-372708,p130Cas linkage to MAPK signaling for integrins,1/206,6/3769,0.16666666666666666,3.0493527508090614,1.2078315817857441,0.2864275435579625,0.7622208052821526,0.7202007477467217,ITGB3,1
R-HSA-429914,Deadenylation-dependent mRNA decay,1/206,6/3769,0.16666666666666666,3.0493527508090614,1.2078315817857441,0.2864275435579625,0.7622208052821526,0.7202007477467217,PARN,1
R-HSA-435354,Zinc transporters,1/206,6/3769,0.16666666666666666,3.0493527508090614,1.2078315817857441,0.2864275435579625,0.7622208052821526,0.7202007477467217,SLC39A14,1
R-HSA-448706,Interleukin-1 processing,1/206,6/3769,0.16666666666666666,3.0493527508090614,1.2078315817857441,0.2864275435579625,0.7622208052821526,0.7202007477467217,IL1B,1
R-HSA-5694530,Cargo concentration in the ER,1/206,6/3769,0.16666666666666666,3.0493527508090614,1.2078315817857441,0.2864275435579625,0.7622208052821526,0.7202007477467217,SERPINA1,1
R-HSA-69017,CDK-mediated phosphorylation and removal of Cdc6,1/206,6/3769,0.16666666666666666,3.0493527508090614,1.2078315817857441,0.2864275435579625,0.7622208052821526,0.7202007477467217,CDK2,1
R-HSA-8854691,Interleukin-20 family signaling,1/206,6/3769,0.16666666666666666,3.0493527508090614,1.2078315817857441,0.2864275435579625,0.7622208052821526,0.7202007477467217,JAK3,1
R-HSA-8949275,RUNX3 Regulates Immune Response and Cell Migration,1/206,6/3769,0.16666666666666666,3.0493527508090614,1.2078315817857441,0.2864275435579625,0.7622208052821526,0.7202007477467217,SPP1,1
R-HSA-8951671,RUNX3 regulates YAP1-mediated transcription,1/206,6/3769,0.16666666666666666,3.0493527508090614,1.2078315817857441,0.2864275435579625,0.7622208052821526,0.7202007477467217,TEAD4,1
R-HSA-8951936,RUNX3 regulates p14-ARF,1/206,6/3769,0.16666666666666666,3.0493527508090614,1.2078315817857441,0.2864275435579625,0.7622208052821526,0.7202007477467217,RUNX1,1
R-HSA-9013973,TICAM1-dependent activation of IRF3/IRF7,1/206,6/3769,0.16666666666666666,3.0493527508090614,1.2078315817857441,0.2864275435579625,0.7622208052821526,0.7202007477467217,TLR3,1
R-HSA-9020558,Interleukin-2 signaling,1/206,6/3769,0.16666666666666666,3.0493527508090614,1.2078315817857441,0.2864275435579625,0.7622208052821526,0.7202007477467217,JAK3,1
R-HSA-9828211,"Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation",1/206,6/3769,0.16666666666666666,3.0493527508090614,1.2078315817857441,0.2864275435579625,0.7622208052821526,0.7202007477467217,TLR3,1
R-HSA-8951664,Neddylation,4/206,50/3769,0.08,1.4636893203883494,0.7935607011532744,0.29091539613779327,0.7710609685142026,0.7285535664126576,CISH/CDKN1A/SPSB1/SOCS3,4
R-HSA-112399,IRS-mediated signalling,2/206,20/3769,0.1,1.8296116504854372,0.8943618508634227,0.2993757318450899,0.7710609685142026,0.7285535664126576,FGF20/FGF2,2
R-HSA-1169408,ISG15 antiviral mechanism,2/206,20/3769,0.1,1.8296116504854372,0.8943618508634227,0.2993757318450899,0.7710609685142026,0.7285535664126576,UBA7/ISG15,2
R-HSA-9035034,RHOF GTPase cycle,2/206,20/3769,0.1,1.8296116504854372,0.8943618508634227,0.2993757318450899,0.7710609685142026,0.7285535664126576,LMNB1/VANGL1,2
R-HSA-9664407,Parasite infection,2/206,20/3769,0.1,1.8296116504854372,0.8943618508634227,0.2993757318450899,0.7710609685142026,0.7285535664126576,HCK/FCGR3A,2
R-HSA-9664417,Leishmania phagocytosis,2/206,20/3769,0.1,1.8296116504854372,0.8943618508634227,0.2993757318450899,0.7710609685142026,0.7285535664126576,HCK/FCGR3A,2
R-HSA-9664422,FCGR3A-mediated phagocytosis,2/206,20/3769,0.1,1.8296116504854372,0.8943618508634227,0.2993757318450899,0.7710609685142026,0.7285535664126576,HCK/FCGR3A,2
R-HSA-9696270,RND2 GTPase cycle,2/206,20/3769,0.1,1.8296116504854372,0.8943618508634227,0.2993757318450899,0.7710609685142026,0.7285535664126576,EPHA2/VANGL1,2
R-HSA-9696273,RND1 GTPase cycle,2/206,20/3769,0.1,1.8296116504854372,0.8943618508634227,0.2993757318450899,0.7710609685142026,0.7285535664126576,EPHA2/VANGL1,2
R-HSA-9833482,PKR-mediated signaling,2/206,20/3769,0.1,1.8296116504854372,0.8943618508634227,0.2993757318450899,0.7710609685142026,0.7285535664126576,TUBB6/ISG15,2
R-HSA-2262752,Cellular responses to stress,14/206,218/3769,0.06422018348623854,1.1749799590273449,0.6399151131699478,0.30254738857660146,0.772082773663353,0.7295190410197133,FKBP5/CCL2/VEGFA/LMNB1/NCF2/ABCG2/CDK2/CDKN1A/HSPA12B/IL6/MYC/PARN/TUBB6/H4C2,14
R-HSA-8878171,Transcriptional regulation by RUNX1,5/206,67/3769,0.07462686567164178,1.365381828720475,0.7255164858129197,0.3028399737461289,0.772082773663353,0.7295190410197133,TJP1/THBS1/RUNX1/SOCS3/H4C2,5
R-HSA-5621481,C-type lectin receptors (CLRs),3/206,36/3769,0.08333333333333333,1.5246763754045307,0.7604924575751533,0.31412245882757794,0.772082773663353,0.7295190410197133,ICAM2/IL1B/FCER1G,3
R-HSA-9855142,Cellular responses to mechanical stimuli,4/206,52/3769,0.07692307692307693,1.40739357729649,0.7112146849711448,0.3160409469765056,0.772082773663353,0.7295190410197133,SPP1/RAMP2/ADM/ITGB3,4
R-HSA-2565942,Regulation of PLK1 Activity at G2/M Transition,2/206,21/3769,0.09523809523809523,1.7424872861766063,0.8203138116301197,0.31997089879857543,0.772082773663353,0.7295190410197133,PLK4/CCNB2,2
R-HSA-1362277,Transcription of E2F targets under negative control by DREAM complex,1/206,7/3769,0.14285714285714285,2.61373092926491,1.0274291738928887,0.32549103705439053,0.772082773663353,0.7295190410197133,MYC,1
R-HSA-1482925,Acyl chain remodelling of PG,1/206,7/3769,0.14285714285714285,2.61373092926491,1.0274291738928887,0.32549103705439053,0.772082773663353,0.7295190410197133,PLA2G5,1
R-HSA-1502540,Signaling by Activin,1/206,7/3769,0.14285714285714285,2.61373092926491,1.0274291738928887,0.32549103705439053,0.772082773663353,0.7295190410197133,INHBB,1
R-HSA-189445,Metabolism of porphyrins,1/206,7/3769,0.14285714285714285,2.61373092926491,1.0274291738928887,0.32549103705439053,0.772082773663353,0.7295190410197133,ABCG2,1
R-HSA-189483,Heme degradation,1/206,7/3769,0.14285714285714285,2.61373092926491,1.0274291738928887,0.32549103705439053,0.772082773663353,0.7295190410197133,ABCG2,1
R-HSA-3301854,Nuclear Pore Complex (NPC) Disassembly,1/206,7/3769,0.14285714285714285,2.61373092926491,1.0274291738928887,0.32549103705439053,0.772082773663353,0.7295190410197133,CCNB2,1
R-HSA-389957,Prefoldin mediated transfer of substrate  to CCT/TriC,1/206,7/3769,0.14285714285714285,2.61373092926491,1.0274291738928887,0.32549103705439053,0.772082773663353,0.7295190410197133,TUBB6,1
R-HSA-389960,Formation of tubulin folding intermediates by CCT/TriC,1/206,7/3769,0.14285714285714285,2.61373092926491,1.0274291738928887,0.32549103705439053,0.772082773663353,0.7295190410197133,TUBB6,1
R-HSA-417957,P2Y receptors,1/206,7/3769,0.14285714285714285,2.61373092926491,1.0274291738928887,0.32549103705439053,0.772082773663353,0.7295190410197133,LPAR4,1
R-HSA-4419969,Depolymerization of the Nuclear Lamina,1/206,7/3769,0.14285714285714285,2.61373092926491,1.0274291738928887,0.32549103705439053,0.772082773663353,0.7295190410197133,LMNB1,1
R-HSA-5621575,CD209 (DC-SIGN) signaling,1/206,7/3769,0.14285714285714285,2.61373092926491,1.0274291738928887,0.32549103705439053,0.772082773663353,0.7295190410197133,ICAM2,1
R-HSA-5658623,FGFRL1 modulation of FGFR1 signaling,1/206,7/3769,0.14285714285714285,2.61373092926491,1.0274291738928887,0.32549103705439053,0.772082773663353,0.7295190410197133,FGF2,1
R-HSA-70221,Glycogen breakdown (glycogenolysis),1/206,7/3769,0.14285714285714285,2.61373092926491,1.0274291738928887,0.32549103705439053,0.772082773663353,0.7295190410197133,PYGL,1
R-HSA-8853884,Transcriptional Regulation by VENTX,1/206,7/3769,0.14285714285714285,2.61373092926491,1.0274291738928887,0.32549103705439053,0.772082773663353,0.7295190410197133,IL6,1
R-HSA-8862803,Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,1/206,7/3769,0.14285714285714285,2.61373092926491,1.0274291738928887,0.32549103705439053,0.772082773663353,0.7295190410197133,LMNB1,1
R-HSA-8863678,Neurodegenerative Diseases,1/206,7/3769,0.14285714285714285,2.61373092926491,1.0274291738928887,0.32549103705439053,0.772082773663353,0.7295190410197133,LMNB1,1
R-HSA-912694,Regulation of IFNA/IFNB signaling,1/206,7/3769,0.14285714285714285,2.61373092926491,1.0274291738928887,0.32549103705439053,0.772082773663353,0.7295190410197133,SOCS3,1
R-HSA-9651496,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),1/206,7/3769,0.14285714285714285,2.61373092926491,1.0274291738928887,0.32549103705439053,0.772082773663353,0.7295190410197133,KLKB1,1
R-HSA-9931510,Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes,1/206,7/3769,0.14285714285714285,2.61373092926491,1.0274291738928887,0.32549103705439053,0.772082773663353,0.7295190410197133,LOC102724428,1
R-HSA-1226099,Signaling by FGFR in disease,2/206,22/3769,0.09090909090909091,1.6632833186231244,0.7501527660605385,0.3404188004173879,0.772082773663353,0.7295190410197133,FGF20/FGF2,2
R-HSA-2428928,IRS-related events triggered by IGF1R,2/206,22/3769,0.09090909090909091,1.6632833186231244,0.7501527660605385,0.3404188004173879,0.772082773663353,0.7295190410197133,FGF20/FGF2,2
R-HSA-3371497,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,2/206,22/3769,0.09090909090909091,1.6632833186231244,0.7501527660605385,0.3404188004173879,0.772082773663353,0.7295190410197133,FKBP5/TUBB6,2
R-HSA-380270,Recruitment of mitotic centrosome proteins and complexes,2/206,22/3769,0.09090909090909091,1.6632833186231244,0.7501527660605385,0.3404188004173879,0.772082773663353,0.7295190410197133,CDK11A/PLK4,2
R-HSA-380287,Centrosome maturation,2/206,22/3769,0.09090909090909091,1.6632833186231244,0.7501527660605385,0.3404188004173879,0.772082773663353,0.7295190410197133,CDK11A/PLK4,2
R-HSA-1500620,Meiosis,3/206,38/3769,0.07894736842105263,1.4444302503832396,0.6620090577933667,0.34469345995202205,0.772082773663353,0.7295190410197133,LMNB1/CDK2/H4C2,3
R-HSA-453279,Mitotic G1 phase and G1/S transition,3/206,38/3769,0.07894736842105263,1.4444302503832396,0.6620090577933667,0.34469345995202205,0.772082773663353,0.7295190410197133,CDK2/CDKN1A/MYC,3
R-HSA-8980692,RHOA GTPase cycle,5/206,72/3769,0.06944444444444445,1.2705636461704424,0.5573039380894523,0.35786706392273493,0.772082773663353,0.7295190410197133,ARAP3/TAGAP/VANGL1/ARHGEF15/ARHGAP8,5
R-HSA-162909,Host Interactions of HIV factors,2/206,23/3769,0.08695652173913043,1.5909666525960322,0.6834773903069159,0.3606741429718119,0.772082773663353,0.7295190410197133,HCK/B2M,2
R-HSA-168643,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",2/206,23/3769,0.08695652173913043,1.5909666525960322,0.6834773903069159,0.3606741429718119,0.772082773663353,0.7295190410197133,NLRP1/CASP4,2
R-HSA-2428924,IGF1R signaling cascade,2/206,23/3769,0.08695652173913043,1.5909666525960322,0.6834773903069159,0.3606741429718119,0.772082773663353,0.7295190410197133,FGF20/FGF2,2
R-HSA-5083635,Defective B3GALTL causes PpS,2/206,23/3769,0.08695652173913043,1.5909666525960322,0.6834773903069159,0.3606741429718119,0.772082773663353,0.7295190410197133,THBS1/ADAMTS9,2
R-HSA-5173214,O-glycosylation of TSR domain-containing proteins,2/206,23/3769,0.08695652173913043,1.5909666525960322,0.6834773903069159,0.3606741429718119,0.772082773663353,0.7295190410197133,THBS1/ADAMTS9,2
R-HSA-74751,Insulin receptor signalling cascade,2/206,23/3769,0.08695652173913043,1.5909666525960322,0.6834773903069159,0.3606741429718119,0.772082773663353,0.7295190410197133,FGF20/FGF2,2
R-HSA-9830369,Kidney development,2/206,23/3769,0.08695652173913043,1.5909666525960322,0.6834773903069159,0.3606741429718119,0.772082773663353,0.7295190410197133,FGF2/PLAC8,2
R-HSA-1181150,Signaling by NODAL,1/206,8/3769,0.125,2.287014563106796,0.8761085809595219,0.36242587128267256,0.772082773663353,0.7295190410197133,CRIPTO,1
R-HSA-1482922,Acyl chain remodelling of PI,1/206,8/3769,0.125,2.287014563106796,0.8761085809595219,0.36242587128267256,0.772082773663353,0.7295190410197133,PLA2G5,1
R-HSA-156711,Polo-like kinase mediated events,1/206,8/3769,0.125,2.287014563106796,0.8761085809595219,0.36242587128267256,0.772082773663353,0.7295190410197133,CCNB2,1
R-HSA-168276,NS1 Mediated Effects on Host Pathways,1/206,8/3769,0.125,2.287014563106796,0.8761085809595219,0.36242587128267256,0.772082773663353,0.7295190410197133,ISG15,1
R-HSA-176408,Regulation of APC/C activators between G1/S and early anaphase,1/206,8/3769,0.125,2.287014563106796,0.8761085809595219,0.36242587128267256,0.772082773663353,0.7295190410197133,CDK2,1
R-HSA-180786,Extension of Telomeres,1/206,8/3769,0.125,2.287014563106796,0.8761085809595219,0.36242587128267256,0.772082773663353,0.7295190410197133,CDK2,1
R-HSA-2032785,YAP1- and WWTR1 (TAZ)-stimulated gene expression,1/206,8/3769,0.125,2.287014563106796,0.8761085809595219,0.36242587128267256,0.772082773663353,0.7295190410197133,TEAD4,1
R-HSA-2173796,SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription,1/206,8/3769,0.125,2.287014563106796,0.8761085809595219,0.36242587128267256,0.772082773663353,0.7295190410197133,MYC,1
R-HSA-389958,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,1/206,8/3769,0.125,2.287014563106796,0.8761085809595219,0.36242587128267256,0.772082773663353,0.7295190410197133,TUBB6,1
R-HSA-400451,Free fatty acids regulate insulin secretion,1/206,8/3769,0.125,2.287014563106796,0.8761085809595219,0.36242587128267256,0.772082773663353,0.7295190410197133,CD36,1
R-HSA-425381,Bicarbonate transporters,1/206,8/3769,0.125,2.287014563106796,0.8761085809595219,0.36242587128267256,0.772082773663353,0.7295190410197133,SLC4A5,1
R-HSA-445144,Signal transduction by L1,1/206,8/3769,0.125,2.287014563106796,0.8761085809595219,0.36242587128267256,0.772082773663353,0.7295190410197133,ITGB3,1
R-HSA-549132,Organic cation/anion/zwitterion transport,1/206,8/3769,0.125,2.287014563106796,0.8761085809595219,0.36242587128267256,0.772082773663353,0.7295190410197133,RUNX1,1
R-HSA-5576890,Phase 3 - rapid repolarisation,1/206,8/3769,0.125,2.287014563106796,0.8761085809595219,0.36242587128267256,0.772082773663353,0.7295190410197133,KCNE4,1
R-HSA-5676594,TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway,1/206,8/3769,0.125,2.287014563106796,0.8761085809595219,0.36242587128267256,0.772082773663353,0.7295190410197133,TNFRSF13C,1
R-HSA-6804757,Regulation of TP53 Degradation,1/206,8/3769,0.125,2.287014563106796,0.8761085809595219,0.36242587128267256,0.772082773663353,0.7295190410197133,CDK2,1
R-HSA-8939243,RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known,1/206,8/3769,0.125,2.287014563106796,0.8761085809595219,0.36242587128267256,0.772082773663353,0.7295190410197133,RUNX1,1
R-HSA-8963889,Assembly of active LPL and LIPC lipase complexes,1/206,8/3769,0.125,2.287014563106796,0.8761085809595219,0.36242587128267256,0.772082773663353,0.7295190410197133,ANGPTL4,1
R-HSA-8982491,Glycogen metabolism,1/206,8/3769,0.125,2.287014563106796,0.8761085809595219,0.36242587128267256,0.772082773663353,0.7295190410197133,PYGL,1
R-HSA-9018678,Biosynthesis of specialized proresolving mediators (SPMs),1/206,8/3769,0.125,2.287014563106796,0.8761085809595219,0.36242587128267256,0.772082773663353,0.7295190410197133,ALOX5AP,1
R-HSA-936964,"Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE)",1/206,8/3769,0.125,2.287014563106796,0.8761085809595219,0.36242587128267256,0.772082773663353,0.7295190410197133,CD14,1
R-HSA-9668328,Sealing of the nuclear envelope (NE) by ESCRT-III,1/206,8/3769,0.125,2.287014563106796,0.8761085809595219,0.36242587128267256,0.772082773663353,0.7295190410197133,TUBB6,1
R-HSA-9671793,Diseases of hemostasis,1/206,8/3769,0.125,2.287014563106796,0.8761085809595219,0.36242587128267256,0.772082773663353,0.7295190410197133,KLKB1,1
R-HSA-9823739,Formation of the anterior neural plate,1/206,8/3769,0.125,2.287014563106796,0.8761085809595219,0.36242587128267256,0.772082773663353,0.7295190410197133,ZIC2,1
R-HSA-9824878,"Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7",1/206,8/3769,0.125,2.287014563106796,0.8761085809595219,0.36242587128267256,0.772082773663353,0.7295190410197133,CD14,1
R-HSA-9827857,Specification of primordial germ cells,1/206,8/3769,0.125,2.287014563106796,0.8761085809595219,0.36242587128267256,0.772082773663353,0.7295190410197133,PDPN,1
R-HSA-1474165,Reproduction,4/206,56/3769,0.07142857142857142,1.306865464632455,0.5562380573427006,0.36671463116952974,0.7770857660497178,0.7342462261511888,LMNB1/CDK2/PDPN/H4C2,4
R-HSA-9018519,Estrogen-dependent gene expression,4/206,56/3769,0.07142857142857142,1.306865464632455,0.5562380573427006,0.36671463116952974,0.7770857660497178,0.7342462261511888,CXCL12/MYC/RUNX1/H4C2,4
R-HSA-157858,Gap junction trafficking and regulation,2/206,24/3769,0.08333333333333333,1.5246763754045307,0.6199438636000288,0.38069697625505616,0.783929440406879,0.7407126192950207,TJP1/TUBB6,2
R-HSA-2404192,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),2/206,24/3769,0.08333333333333333,1.5246763754045307,0.6199438636000288,0.38069697625505616,0.783929440406879,0.7407126192950207,FGF20/FGF2,2
R-HSA-381340,Transcriptional regulation of white adipocyte differentiation,2/206,24/3769,0.08333333333333333,1.5246763754045307,0.6199438636000288,0.38069697625505616,0.783929440406879,0.7407126192950207,CD36/ANGPTL4,2
R-HSA-5654736,Signaling by FGFR1,2/206,24/3769,0.08333333333333333,1.5246763754045307,0.6199438636000288,0.38069697625505616,0.783929440406879,0.7407126192950207,FGF20/FGF2,2
R-HSA-8848021,Signaling by PTK6,2/206,24/3769,0.08333333333333333,1.5246763754045307,0.6199438636000288,0.38069697625505616,0.783929440406879,0.7407126192950207,CDK2/SOCS3,2
R-HSA-9006927,Signaling by Non-Receptor Tyrosine Kinases,2/206,24/3769,0.08333333333333333,1.5246763754045307,0.6199438636000288,0.38069697625505616,0.783929440406879,0.7407126192950207,CDK2/SOCS3,2
R-HSA-9031628,NGF-stimulated transcription,2/206,24/3769,0.08333333333333333,1.5246763754045307,0.6199438636000288,0.38069697625505616,0.783929440406879,0.7407126192950207,F3/EGR4,2
R-HSA-69278,"Cell Cycle, Mitotic",9/206,145/3769,0.06206896551724138,1.1356210244392366,0.40040369194624537,0.3962907274469169,0.783929440406879,0.7407126192950207,CDK11A/LMNB1/CDK2/CDKN1A/MYC/PLK4/CCNB2/TUBB6/H4C2,9
R-HSA-112409,RAF-independent MAPK1/3 activation,1/206,9/3769,0.1111111111111111,2.0329018338727076,0.7458775348940413,0.39734750662321205,0.783929440406879,0.7407126192950207,IL6,1
R-HSA-140875,Common Pathway of Fibrin Clot Formation,1/206,9/3769,0.1111111111111111,2.0329018338727076,0.7458775348940413,0.39734750662321205,0.783929440406879,0.7407126192950207,THBD,1
R-HSA-164938,Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters,1/206,9/3769,0.1111111111111111,2.0329018338727076,0.7458775348940413,0.39734750662321205,0.783929440406879,0.7407126192950207,B2M,1
R-HSA-174143,APC/C-mediated degradation of cell cycle proteins,1/206,9/3769,0.1111111111111111,2.0329018338727076,0.7458775348940413,0.39734750662321205,0.783929440406879,0.7407126192950207,CDK2,1
R-HSA-190840,Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane,1/206,9/3769,0.1111111111111111,2.0329018338727076,0.7458775348940413,0.39734750662321205,0.783929440406879,0.7407126192950207,TUBB6,1
R-HSA-190872,Transport of connexons to the plasma membrane,1/206,9/3769,0.1111111111111111,2.0329018338727076,0.7458775348940413,0.39734750662321205,0.783929440406879,0.7407126192950207,TUBB6,1
R-HSA-196757,Metabolism of folate and pterines,1/206,9/3769,0.1111111111111111,2.0329018338727076,0.7458775348940413,0.39734750662321205,0.783929440406879,0.7407126192950207,MTHFD2,1
R-HSA-197264,Nicotinamide salvage,1/206,9/3769,0.1111111111111111,2.0329018338727076,0.7458775348940413,0.39734750662321205,0.783929440406879,0.7407126192950207,NAMPT,1
R-HSA-2871837,FCERI mediated NF-kB activation,1/206,9/3769,0.1111111111111111,2.0329018338727076,0.7458775348940413,0.39734750662321205,0.783929440406879,0.7407126192950207,FCER1G,1
R-HSA-389977,Post-chaperonin tubulin folding pathway,1/206,9/3769,0.1111111111111111,2.0329018338727076,0.7458775348940413,0.39734750662321205,0.783929440406879,0.7407126192950207,TUBB6,1
R-HSA-391160,Signal regulatory protein family interactions,1/206,9/3769,0.1111111111111111,2.0329018338727076,0.7458775348940413,0.39734750662321205,0.783929440406879,0.7407126192950207,SFTPA2,1
R-HSA-418038,Nucleotide-like (purinergic) receptors,1/206,9/3769,0.1111111111111111,2.0329018338727076,0.7458775348940413,0.39734750662321205,0.783929440406879,0.7407126192950207,LPAR4,1
R-HSA-453276,Regulation of mitotic cell cycle,1/206,9/3769,0.1111111111111111,2.0329018338727076,0.7458775348940413,0.39734750662321205,0.783929440406879,0.7407126192950207,CDK2,1
R-HSA-5218921,VEGFR2 mediated cell proliferation,1/206,9/3769,0.1111111111111111,2.0329018338727076,0.7458775348940413,0.39734750662321205,0.783929440406879,0.7407126192950207,VEGFA,1
R-HSA-6806003,Regulation of TP53 Expression and Degradation,1/206,9/3769,0.1111111111111111,2.0329018338727076,0.7458775348940413,0.39734750662321205,0.783929440406879,0.7407126192950207,CDK2,1
R-HSA-68949,Orc1 removal from chromatin,1/206,9/3769,0.1111111111111111,2.0329018338727076,0.7458775348940413,0.39734750662321205,0.783929440406879,0.7407126192950207,CDK2,1
R-HSA-8963743,Digestion and absorption,1/206,9/3769,0.1111111111111111,2.0329018338727076,0.7458775348940413,0.39734750662321205,0.783929440406879,0.7407126192950207,SLC2A5,1
R-HSA-9615710,Late endosomal microautophagy,1/206,9/3769,0.1111111111111111,2.0329018338727076,0.7458775348940413,0.39734750662321205,0.783929440406879,0.7407126192950207,VPS28,1
R-HSA-9734009,Defective Intrinsic Pathway for Apoptosis,1/206,9/3769,0.1111111111111111,2.0329018338727076,0.7458775348940413,0.39734750662321205,0.783929440406879,0.7407126192950207,LMNB1,1
R-HSA-9861718,Regulation of pyruvate metabolism,1/206,9/3769,0.1111111111111111,2.0329018338727076,0.7458775348940413,0.39734750662321205,0.783929440406879,0.7407126192950207,PDK1,1
R-HSA-5654738,Signaling by FGFR2,2/206,25/3769,0.08,1.4636893203883494,0.5592555771719044,0.40045224953239067,0.7862106619629669,0.7428680806247102,FGF20/FGF2,2
R-HSA-416476,G alpha (q) signalling events,8/206,128/3769,0.0625,1.143507281553398,0.3971455760427717,0.40046685403357113,0.7862106619629669,0.7428680806247102,EDN1/EDN3/F2RL3/HTR2B/HCRTR2/RGS16/LPAR4/FPR2,8
R-HSA-977225,Amyloid fiber formation,3/206,42/3769,0.07142857142857142,1.306865464632455,0.480810684074687,0.40532593933822714,0.7867396365370624,0.7433678936462946,CALCA/B2M/H4C2,3
R-HSA-9856651,MITF-M-dependent gene expression,3/206,42/3769,0.07142857142857142,1.306865464632455,0.480810684074687,0.40532593933822714,0.7867396365370624,0.7433678936462946,CDK2/CDKN1A/BCL2A1,3
R-HSA-73887,Death Receptor Signaling,4/206,60/3769,0.06666666666666667,1.2197411003236245,0.4125149091251574,0.41721995188759853,0.7867396365370624,0.7433678936462946,TNFRSF10B/TNFSF10/TNFRSF10D/ARHGEF15,4
R-HSA-168928,DDX58/IFIH1-mediated induction of interferon-alpha/beta,2/206,26/3769,0.07692307692307693,1.40739357729649,0.5011550193389367,0.4199093996953638,0.7867396365370624,0.7433678936462946,UBA7/ISG15,2
R-HSA-9856649,Transcriptional and post-translational regulation of MITF-M expression and activity,2/206,26/3769,0.07692307692307693,1.40739357729649,0.5011550193389367,0.4199093996953638,0.7867396365370624,0.7433678936462946,EDN1/EDN3,2
R-HSA-9909396,Circadian clock,2/206,26/3769,0.07692307692307693,1.40739357729649,0.5011550193389367,0.4199093996953638,0.7867396365370624,0.7433678936462946,NAMPT/LOC102724428,2
R-HSA-162906,HIV Infection,3/206,43/3769,0.06976744186046512,1.2764732445247235,0.43837629088337476,0.4202600730909256,0.7867396365370624,0.7433678936462946,HCK/VPS28/B2M,3
R-HSA-168164,Toll Like Receptor 3 (TLR3) Cascade,3/206,43/3769,0.06976744186046512,1.2764732445247235,0.43837629088337476,0.4202600730909256,0.7867396365370624,0.7433678936462946,TIFA/TLR3/TNIP2,3
R-HSA-3000178,ECM proteoglycans,3/206,43/3769,0.06976744186046512,1.2764732445247235,0.43837629088337476,0.4202600730909256,0.7867396365370624,0.7433678936462946,ASPN/COL3A1/ITGB3,3
R-HSA-9758941,Gastrulation,3/206,43/3769,0.06976744186046512,1.2764732445247235,0.43837629088337476,0.4202600730909256,0.7867396365370624,0.7433678936462946,ZIC2/FGF2/TEAD4,3
R-HSA-5663202,Diseases of signal transduction by growth factor receptors and second messengers,10/206,166/3769,0.060240963855421686,1.1021756930635163,0.32370592695012906,0.4224799581678663,0.7867396365370624,0.7433678936462946,FGF20/NR4A1/CDKN1A/RAC2/MYC/PIM1/FGF2/BCL2A1/PIK3AP1/ITGB3,10
R-HSA-388396,GPCR downstream signalling,19/206,327/3769,0.0581039755351682,1.0630771057866453,0.2869599892932276,0.4246003192669429,0.7867396365370624,0.7433678936462946,EDN1/CXCL12/CALCA/EDN3/F2RL3/RAMP2/HTR2B/HCRTR2/GPR84/RGS16/LPAR4/ADM/CXCR1/CCR1/CX3CR1/FPR2/FPR1/CXCR2/ARHGEF15,19
R-HSA-381426,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),4/206,61/3769,0.06557377049180328,1.1997453445806145,0.3781402151273383,0.42972733289942666,0.7867396365370624,0.7433678936462946,SPP1/IL6/PAPPA/SERPINA1,4
R-HSA-1234174,Cellular response to hypoxia,1/206,10/3769,0.1,1.8296116504854372,0.6315675758067972,0.4303651698241744,0.7867396365370624,0.7433678936462946,VEGFA,1
R-HSA-140837,Intrinsic Pathway of Fibrin Clot Formation,1/206,10/3769,0.1,1.8296116504854372,0.6315675758067972,0.4303651698241744,0.7867396365370624,0.7433678936462946,KLKB1,1
R-HSA-1592389,Activation of Matrix Metalloproteinases,1/206,10/3769,0.1,1.8296116504854372,0.6315675758067972,0.4303651698241744,0.7867396365370624,0.7433678936462946,KLKB1,1
R-HSA-2022870,Chondroitin sulfate biosynthesis,1/206,10/3769,0.1,1.8296116504854372,0.6315675758067972,0.4303651698241744,0.7867396365370624,0.7433678936462946,CHSY1,1
R-HSA-204005,COPII-mediated vesicle transport,1/206,10/3769,0.1,1.8296116504854372,0.6315675758067972,0.4303651698241744,0.7867396365370624,0.7433678936462946,SERPINA1,1
R-HSA-210993,Tie2 Signaling,1/206,10/3769,0.1,1.8296116504854372,0.6315675758067972,0.4303651698241744,0.7867396365370624,0.7433678936462946,ANGPT2,1
R-HSA-2173793,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,1/206,10/3769,0.1,1.8296116504854372,0.6315675758067972,0.4303651698241744,0.7867396365370624,0.7433678936462946,MYC,1
R-HSA-354192,Integrin signaling,1/206,10/3769,0.1,1.8296116504854372,0.6315675758067972,0.4303651698241744,0.7867396365370624,0.7433678936462946,ITGB3,1
R-HSA-4641263,Regulation of FZD by ubiquitination,1/206,10/3769,0.1,1.8296116504854372,0.6315675758067972,0.4303651698241744,0.7867396365370624,0.7433678936462946,LGR6,1
R-HSA-5621480,Dectin-2 family,1/206,10/3769,0.1,1.8296116504854372,0.6315675758067972,0.4303651698241744,0.7867396365370624,0.7433678936462946,FCER1G,1
R-HSA-622312,Inflammasomes,1/206,10/3769,0.1,1.8296116504854372,0.6315675758067972,0.4303651698241744,0.7867396365370624,0.7433678936462946,NLRP1,1
R-HSA-912526,Interleukin receptor SHC signaling,1/206,10/3769,0.1,1.8296116504854372,0.6315675758067972,0.4303651698241744,0.7867396365370624,0.7433678936462946,JAK3,1
R-HSA-9753281,Paracetamol ADME,1/206,10/3769,0.1,1.8296116504854372,0.6315675758067972,0.4303651698241744,0.7867396365370624,0.7433678936462946,ABCG2,1
R-HSA-9937080,Developmental Lineage of Multipotent Pancreatic Progenitor Cells,1/206,10/3769,0.1,1.8296116504854372,0.6315675758067972,0.4303651698241744,0.7867396365370624,0.7433678936462946,FGF2,1
R-HSA-2555396,Mitotic Metaphase and Anaphase,3/206,44/3769,0.06818181818181818,1.2474624889673431,0.3969663759605258,0.43506936958400944,0.7867396365370624,0.7433678936462946,LMNB1/CCNB2/TUBB6,3
R-HSA-4420097,VEGFA-VEGFR2 Pathway,3/206,44/3769,0.06818181818181818,1.2474624889673431,0.3969663759605258,0.43506936958400944,0.7867396365370624,0.7433678936462946,VEGFA/NCF2/ITGB3,3
R-HSA-68882,Mitotic Anaphase,3/206,44/3769,0.06818181818181818,1.2474624889673431,0.3969663759605258,0.43506936958400944,0.7867396365370624,0.7433678936462946,LMNB1/CCNB2/TUBB6,3
R-HSA-9818564,Epigenetic regulation of gene expression by MLL3 and MLL4 complexes,3/206,44/3769,0.06818181818181818,1.2474624889673431,0.3969663759605258,0.43506936958400944,0.7867396365370624,0.7433678936462946,CD36/ANGPTL4/H4C2,3
R-HSA-9841922,MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis,3/206,44/3769,0.06818181818181818,1.2474624889673431,0.3969663759605258,0.43506936958400944,0.7867396365370624,0.7433678936462946,CD36/ANGPTL4/H4C2,3
R-HSA-9851695,Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes,3/206,44/3769,0.06818181818181818,1.2474624889673431,0.3969663759605258,0.43506936958400944,0.7867396365370624,0.7433678936462946,CD36/ANGPTL4/H4C2,3
R-HSA-9860931,Response of endothelial cells to shear stress,3/206,44/3769,0.06818181818181818,1.2474624889673431,0.3969663759605258,0.43506936958400944,0.7867396365370624,0.7433678936462946,RAMP2/ADM/ITGB3,3
R-HSA-380320,Recruitment of NuMA to mitotic centrosomes,2/206,27/3769,0.07407407407407407,1.3552678892484717,0.44541731156367265,0.439041969453267,0.7867396365370624,0.7433678936462946,PLK4/TUBB6,2
R-HSA-5693607,Processing of DNA double-strand break ends,2/206,27/3769,0.07407407407407407,1.3552678892484717,0.44541731156367265,0.439041969453267,0.7867396365370624,0.7433678936462946,CDK2/H4C2,2
R-HSA-6809371,Formation of the cornified envelope,2/206,27/3769,0.07407407407407407,1.3552678892484717,0.44541731156367265,0.439041969453267,0.7867396365370624,0.7433678936462946,DSC2/SPINK9,2
R-HSA-9013405,RHOD GTPase cycle,2/206,27/3769,0.07407407407407407,1.3552678892484717,0.44541731156367265,0.439041969453267,0.7867396365370624,0.7433678936462946,LMNB1/VANGL1,2
R-HSA-917937,Iron uptake and transport,2/206,27/3769,0.07407407407407407,1.3552678892484717,0.44541731156367265,0.439041969453267,0.7867396365370624,0.7433678936462946,ABCG2/STEAP4,2
R-HSA-166166,MyD88-independent TLR4 cascade,3/206,45/3769,0.06666666666666667,1.2197411003236245,0.35652817955863764,0.44973838242479103,0.7951125448924692,0.751279216476359,TIFA/TNIP2/CD14,3
R-HSA-68875,Mitotic Prophase,3/206,45/3769,0.06666666666666667,1.2197411003236245,0.35652817955863764,0.44973838242479103,0.7951125448924692,0.751279216476359,LMNB1/CCNB2/H4C2,3
R-HSA-937061,TRIF (TICAM1)-mediated TLR4 signaling,3/206,45/3769,0.06666666666666667,1.2197411003236245,0.35652817955863764,0.44973838242479103,0.7951125448924692,0.751279216476359,TIFA/TNIP2/CD14,3
R-HSA-975138,TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,3/206,45/3769,0.06666666666666667,1.2197411003236245,0.35652817955863764,0.44973838242479103,0.7951125448924692,0.751279216476359,TIFA/TNIP2/CD14,3
R-HSA-975155,MyD88 dependent cascade initiated on endosome,3/206,45/3769,0.06666666666666667,1.2197411003236245,0.35652817955863764,0.44973838242479103,0.7951125448924692,0.751279216476359,TIFA/TNIP2/CD14,3
R-HSA-9006925,Intracellular signaling by second messengers,7/206,116/3769,0.0603448275862069,1.1040759959825912,0.27373849818490953,0.45038957225227483,0.7951125448924692,0.751279216476359,FGF20/IL1RL1/NR4A1/CDKN1A/RAC2/FGF2/PIK3AP1,7
R-HSA-1221632,Meiotic synapsis,2/206,28/3769,0.07142857142857142,1.306865464632455,0.3918450115617703,0.4578272535330832,0.7951125448924692,0.751279216476359,LMNB1/H4C2,2
R-HSA-8986944,Transcriptional Regulation by MECP2,2/206,28/3769,0.07142857142857142,1.306865464632455,0.3918450115617703,0.4578272535330832,0.7951125448924692,0.751279216476359,SLC2A3/FKBP5,2
R-HSA-1482801,Acyl chain remodelling of PS,1/206,11/3769,0.09090909090909091,1.6632833186231244,0.5296612191424174,0.46158218898251957,0.7951125448924692,0.751279216476359,PLA2G5,1
R-HSA-176187,Activation of ATR in response to replication stress,1/206,11/3769,0.09090909090909091,1.6632833186231244,0.5296612191424174,0.46158218898251957,0.7951125448924692,0.751279216476359,CDK2,1
R-HSA-3000480,Scavenging by Class A Receptors,1/206,11/3769,0.09090909090909091,1.6632833186231244,0.5296612191424174,0.46158218898251957,0.7951125448924692,0.751279216476359,COL3A1,1
R-HSA-390666,Serotonin receptors,1/206,11/3769,0.09090909090909091,1.6632833186231244,0.5296612191424174,0.46158218898251957,0.7951125448924692,0.751279216476359,HTR2B,1
R-HSA-5576893,Phase 2 - plateau phase,1/206,11/3769,0.09090909090909091,1.6632833186231244,0.5296612191424174,0.46158218898251957,0.7951125448924692,0.751279216476359,KCNE4,1
R-HSA-6802948,Signaling by high-kinase activity BRAF mutants,1/206,11/3769,0.09090909090909091,1.6632833186231244,0.5296612191424174,0.46158218898251957,0.7951125448924692,0.751279216476359,ITGB3,1
R-HSA-69052,Switching of origins to a post-replicative state,1/206,11/3769,0.09090909090909091,1.6632833186231244,0.5296612191424174,0.46158218898251957,0.7951125448924692,0.751279216476359,CDK2,1
R-HSA-8950505,Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation,1/206,11/3769,0.09090909090909091,1.6632833186231244,0.5296612191424174,0.46158218898251957,0.7951125448924692,0.751279216476359,LMNB1,1
R-HSA-9680350,Signaling by CSF1 (M-CSF) in myeloid cells,1/206,11/3769,0.09090909090909091,1.6632833186231244,0.5296612191424174,0.46158218898251957,0.7951125448924692,0.751279216476359,HCK,1
R-HSA-9860927,"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",1/206,11/3769,0.09090909090909091,1.6632833186231244,0.5296612191424174,0.46158218898251957,0.7951125448924692,0.751279216476359,ITGB3,1
R-HSA-168138,Toll Like Receptor 9 (TLR9) Cascade,3/206,46/3769,0.06521739130434782,1.193224989447024,0.31701282774343187,0.46425285635603286,0.7962880898098122,0.752389955415277,TIFA/TNIP2/CD14,3
R-HSA-69481,G2/M Checkpoints,3/206,46/3769,0.06521739130434782,1.193224989447024,0.31701282774343187,0.46425285635603286,0.7962880898098122,0.752389955415277,CDK2/CCNB2/H4C2,3
R-HSA-9694516,SARS-CoV-2 Infection,5/206,82/3769,0.06097560975609756,1.1156168600520957,0.2544911440044145,0.4679260643518478,0.8008734562945087,0.7567225377170008,TLR8/TJP1/TLR2/B2M/ISG15,5
R-HSA-199977,ER to Golgi Anterograde Transport,2/206,29/3769,0.06896551724137931,1.2618011382658185,0.34026389915909516,0.4762459709895831,0.8133753150589682,0.7685351882875329,TUBB6/SERPINA1,2
R-HSA-73894,DNA Repair,4/206,66/3769,0.06060606060606061,1.1088555457487497,0.21449976331066864,0.49102486012949564,0.8229459096176375,0.77757817072748725,CDK2/UBA7/ISG15/H4C2,4
R-HSA-1482788,Acyl chain remodelling of PC,1/206,12/3769,0.08333333333333333,1.5246763754045307,0.4376658703912442,0.4910963106082781,0.8229459096176375,0.77757817072748725,PLA2G5,1
R-HSA-210991,Basigin interactions,1/206,12/3769,0.08333333333333333,1.5246763754045307,0.4376658703912442,0.4910963106082781,0.8229459096176375,0.77757817072748725,SLC16A3,1
R-HSA-5683826,Surfactant metabolism,1/206,12/3769,0.08333333333333333,1.5246763754045307,0.4376658703912442,0.4910963106082781,0.8229459096176375,0.77757817072748725,SFTPA2,1
R-HSA-68962,Activation of the pre-replicative complex,1/206,12/3769,0.08333333333333333,1.5246763754045307,0.4376658703912442,0.4910963106082781,0.8229459096176375,0.77757817072748725,CDK2,1
R-HSA-72306,tRNA processing,1/206,12/3769,0.08333333333333333,1.5246763754045307,0.4376658703912442,0.4910963106082781,0.8229459096176375,0.77757817072748725,TRMT9B,1
R-HSA-9013695,NOTCH4 Intracellular Domain Regulates Transcription,1/206,12/3769,0.08333333333333333,1.5246763754045307,0.4376658703912442,0.4910963106082781,0.8229459096176375,0.77757817072748725,ACTA2,1
R-HSA-9725371,Nuclear events stimulated by ALK signaling in cancer,1/206,12/3769,0.08333333333333333,1.5246763754045307,0.4376658703912442,0.4910963106082781,0.8229459096176375,0.77757817072748725,BCL2A1,1
R-HSA-9768919,NPAS4 regulates expression of target genes,1/206,12/3769,0.08333333333333333,1.5246763754045307,0.4376658703912442,0.4910963106082781,0.8229459096176375,0.77757817072748725,NAMPT,1
R-HSA-9917777,Epigenetic regulation by WDR5-containing histone modifying complexes,3/206,48/3769,0.0625,1.143507281553398,0.24057243690904972,0.49276690041497384,0.8231181942651081,0.7777409575880319,CD36/ANGPTL4/H4C2,3
R-HSA-6805567,Keratinization,2/206,30/3769,0.06666666666666667,1.2197411003236245,0.2905195318836402,0.4942819618495843,0.8231181942651081,0.7777409575880319,DSC2/SPINK9,2
R-HSA-9013409,RHOJ GTPase cycle,2/206,30/3769,0.06666666666666667,1.2197411003236245,0.2905195318836402,0.4942819618495843,0.8231181942651081,0.7777409575880319,SLC1A5/VANGL1,2
R-HSA-157579,Telomere Maintenance,2/206,31/3769,0.06451612903225806,1.180394613216411,0.2424744089335875,0.511921906429115,0.8422957461945783,0.795861280654316,CDK2/H4C2,2
R-HSA-3928665,EPH-ephrin mediated repulsion of cells,2/206,31/3769,0.06451612903225806,1.180394613216411,0.2424744089335875,0.511921906429115,0.8422957461945783,0.795861280654316,EPHA2/EFNA1,2
R-HSA-912446,Meiotic recombination,2/206,31/3769,0.06451612903225806,1.180394613216411,0.2424744089335875,0.511921906429115,0.8422957461945783,0.795861280654316,CDK2/H4C2,2
R-HSA-983231,Factors involved in megakaryocyte development and platelet production,4/206,68/3769,0.058823529411764705,1.0762421473443746,0.1525355876361719,0.5147989099293513,0.8422957461945783,0.795861280654316,CDK2/IRF1/TUBB6/MAFF,4
R-HSA-9012999,RHO GTPase cycle,11/206,197/3769,0.05583756345177665,1.0216105662609039,0.07490739270377636,0.5170863355410088,0.8422957461945783,0.795861280654316,SLC1A5/LMNB1/NCF2/ARAP3/TRIP10/RAC2/EPHA2/TAGAP/VANGL1/ARHGEF15/ARHGAP8,11
R-HSA-1368108,"BMAL1:CLOCK,NPAS2 activates circadian expression",1/206,13/3769,0.07692307692307693,1.40739357729649,0.35375632072468466,0.5189999997258441,0.8422957461945783,0.795861280654316,NAMPT,1
R-HSA-1482839,Acyl chain remodelling of PE,1/206,13/3769,0.07692307692307693,1.40739357729649,0.35375632072468466,0.5189999997258441,0.8422957461945783,0.795861280654316,PLA2G5,1
R-HSA-3238698,WNT ligand biogenesis and trafficking,1/206,13/3769,0.07692307692307693,1.40739357729649,0.35375632072468466,0.5189999997258441,0.8422957461945783,0.795861280654316,WNT7A,1
R-HSA-5626467,RHO GTPases activate IQGAPs,1/206,13/3769,0.07692307692307693,1.40739357729649,0.35375632072468466,0.5189999997258441,0.8422957461945783,0.795861280654316,TUBB6,1
R-HSA-5674135,MAP2K and MAPK activation,1/206,13/3769,0.07692307692307693,1.40739357729649,0.35375632072468466,0.5189999997258441,0.8422957461945783,0.795861280654316,ITGB3,1
R-HSA-70268,Pyruvate metabolism,1/206,13/3769,0.07692307692307693,1.40739357729649,0.35375632072468466,0.5189999997258441,0.8422957461945783,0.795861280654316,PDK1,1
R-HSA-75876,Synthesis of very long-chain fatty acyl-CoAs,1/206,13/3769,0.07692307692307693,1.40739357729649,0.35375632072468466,0.5189999997258441,0.8422957461945783,0.795861280654316,ACSL5,1
R-HSA-194138,Signaling by VEGF,3/206,50/3769,0.06,1.0977669902912621,0.16731901718202408,0.5205198431539528,0.8422957461945783,0.795861280654316,VEGFA/NCF2/ITGB3,3
R-HSA-9609646,HCMV Infection,3/206,50/3769,0.06,1.0977669902912621,0.16731901718202408,0.5205198431539528,0.8422957461945783,0.795861280654316,VPS28/TUBB6/H4C2,3
R-HSA-9006934,Signaling by Receptor Tyrosine Kinases,14/206,253/3769,0.05533596837944664,1.0124333243792931,0.04922709839292953,0.5226990290983724,0.8441167788463635,0.7975819225843161,FGF20/JAK3/CXCL12/VEGFA/NCF2/F3/SPP1/EGR4/MYC/THBS1/FGF2/MST1R/COL3A1/ITGB3,14
R-HSA-9843745,Adipogenesis,2/206,32/3769,0.0625,1.143507281553398,0.19600562004958927,0.5291550657698136,0.8475279194479637,0.8008050122650449,CD36/ANGPTL4,2
R-HSA-5173105,O-linked glycosylation,3/206,51/3769,0.058823529411764705,1.0762421473443746,0.1317973448010337,0.534086817402891,0.8475279194479637,0.8008050122650449,GALNT5/THBS1/ADAMTS9,3
R-HSA-68877,Mitotic Prometaphase,3/206,51/3769,0.058823529411764705,1.0762421473443746,0.1317973448010337,0.534086817402891,0.8475279194479637,0.8008050122650449,PLK4/CCNB2/TUBB6,3
R-HSA-69620,Cell Cycle Checkpoints,4/206,70/3769,0.05714285714285714,1.0454923717059639,0.09236907178141746,0.5380557168379416,0.8475279194479637,0.8008050122650449,CDK2/CDKN1A/CCNB2/H4C2,4
R-HSA-1660661,Sphingolipid de novo biosynthesis,1/206,14/3769,0.07142857142857142,1.306865464632455,0.27655926217219334,0.545380723915534,0.8475279194479637,0.8008050122650449,ABCG2,1
R-HSA-168638,NOD1/2 Signaling Pathway,1/206,14/3769,0.07142857142857142,1.306865464632455,0.27655926217219334,0.545380723915534,0.8475279194479637,0.8008050122650449,CASP4,1
R-HSA-196807,Nicotinate metabolism,1/206,14/3769,0.07142857142857142,1.306865464632455,0.27655926217219334,0.545380723915534,0.8475279194479637,0.8008050122650449,NAMPT,1
R-HSA-2424491,DAP12 signaling,1/206,14/3769,0.07142857142857142,1.306865464632455,0.27655926217219334,0.545380723915534,0.8475279194479637,0.8008050122650449,B2M,1
R-HSA-445989,TAK1-dependent IKK and NF-kappa-B activation,1/206,14/3769,0.07142857142857142,1.306865464632455,0.27655926217219334,0.545380723915534,0.8475279194479637,0.8008050122650449,TIFA,1
R-HSA-6807505,RNA polymerase II transcribes snRNA genes,1/206,14/3769,0.07142857142857142,1.306865464632455,0.27655926217219334,0.545380723915534,0.8475279194479637,0.8008050122650449,NABP1,1
R-HSA-75105,Fatty acyl-CoA biosynthesis,1/206,14/3769,0.07142857142857142,1.306865464632455,0.27655926217219334,0.545380723915534,0.8475279194479637,0.8008050122650449,ACSL5,1
R-HSA-9020591,Interleukin-12 signaling,1/206,14/3769,0.07142857142857142,1.306865464632455,0.27655926217219334,0.545380723915534,0.8475279194479637,0.8008050122650449,LMNB1,1
R-HSA-9607240,FLT3 Signaling,1/206,14/3769,0.07142857142857142,1.306865464632455,0.27655926217219334,0.545380723915534,0.8475279194479637,0.8008050122650449,HCK,1
R-HSA-9619483,Activation of AMPK downstream of NMDARs,1/206,14/3769,0.07142857142857142,1.306865464632455,0.27655926217219334,0.545380723915534,0.8475279194479637,0.8008050122650449,TUBB6,1
R-HSA-9660826,Purinergic signaling in leishmaniasis infection,1/206,14/3769,0.07142857142857142,1.306865464632455,0.27655926217219334,0.545380723915534,0.8475279194479637,0.8008050122650449,IL1B,1
R-HSA-9664424,Cell recruitment (pro-inflammatory response),1/206,14/3769,0.07142857142857142,1.306865464632455,0.27655926217219334,0.545380723915534,0.8475279194479637,0.8008050122650449,IL1B,1
R-HSA-9839373,Signaling by TGFBR3,1/206,14/3769,0.07142857142857142,1.306865464632455,0.27655926217219334,0.545380723915534,0.8475279194479637,0.8008050122650449,FGF2,1
R-HSA-190236,Signaling by FGFR,2/206,33/3769,0.06060606060606061,1.1088555457487497,0.15100288391738345,0.5459730417417593,0.8475279194479637,0.8008050122650449,FGF20/FGF2,2
R-HSA-5693567,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),2/206,33/3769,0.06060606060606061,1.1088555457487497,0.15100288391738345,0.5459730417417593,0.8475279194479637,0.8008050122650449,CDK2/H4C2,2
R-HSA-9662361,Sensory processing of sound by outer hair cells of the cochlea,2/206,33/3769,0.06060606060606061,1.1088555457487497,0.15100288391738345,0.5459730417417593,0.8475279194479637,0.8008050122650449,CDH23/STRC,2
R-HSA-1474228,Degradation of the extracellular matrix,4/206,72/3769,0.05555555555555555,1.0164509169363538,0.033885412632401204,0.560745219527486,0.8525335253621964,0.8055346668446274,SPP1/ADAMTS9/KLKB1/COL3A1,4
R-HSA-2500257,Resolution of Sister Chromatid Cohesion,2/206,34/3769,0.058823529411764705,1.0762421473443746,0.10736690178190438,0.5623695554545047,0.8525335253621964,0.8055346668446274,CCNB2/TUBB6,2
R-HSA-3906995,Diseases associated with O-glycosylation of proteins,2/206,34/3769,0.058823529411764705,1.0762421473443746,0.10736690178190438,0.5623695554545047,0.8525335253621964,0.8055346668446274,THBS1/ADAMTS9,2
R-HSA-9824439,Bacterial Infection Pathways,2/206,34/3769,0.058823529411764705,1.0762421473443746,0.10736690178190438,0.5623695554545047,0.8525335253621964,0.8055346668446274,TLR2/B2M,2
R-HSA-9856530,High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,2/206,34/3769,0.058823529411764705,1.0762421473443746,0.10736690178190438,0.5623695554545047,0.8525335253621964,0.8055346668446274,RAMP2/ADM,2
R-HSA-1483166,Synthesis of PA,1/206,15/3769,0.06666666666666667,1.2197411003236245,0.20501750137737104,0.570321222150794,0.8525335253621964,0.8055346668446274,PLA2G5,1
R-HSA-3371453,Regulation of HSF1-mediated heat shock response,1/206,15/3769,0.06666666666666667,1.2197411003236245,0.20501750137737104,0.570321222150794,0.8525335253621964,0.8055346668446274,HSPA12B,1
R-HSA-447115,Interleukin-12 family signaling,1/206,15/3769,0.06666666666666667,1.2197411003236245,0.20501750137737104,0.570321222150794,0.8525335253621964,0.8055346668446274,LMNB1,1
R-HSA-8964038,LDL clearance,1/206,15/3769,0.06666666666666667,1.2197411003236245,0.20501750137737104,0.570321222150794,0.8525335253621964,0.8055346668446274,LSR,1
R-HSA-9692916,SARS-CoV-1 activates/modulates innate immune responses,1/206,15/3769,0.06666666666666667,1.2197411003236245,0.20501750137737104,0.570321222150794,0.8525335253621964,0.8055346668446274,RUNX1,1
R-HSA-5693538,Homology Directed Repair,2/206,35/3769,0.05714285714285714,1.0454923717059639,0.06500796788448185,0.5783402427067049,0.8525335253621964,0.8055346668446274,CDK2/H4C2,2
R-HSA-73886,Chromosome Maintenance,2/206,35/3769,0.05714285714285714,1.0454923717059639,0.06500796788448185,0.5783402427067049,0.8525335253621964,0.8055346668446274,CDK2/H4C2,2
R-HSA-8878166,Transcriptional regulation by RUNX2,2/206,35/3769,0.05714285714285714,1.0454923717059639,0.06500796788448185,0.5783402427067049,0.8525335253621964,0.8055346668446274,CDKN1A/RUNX1,2
R-HSA-9610379,HCMV Late Events,2/206,35/3769,0.05714285714285714,1.0454923717059639,0.06500796788448185,0.5783402427067049,0.8525335253621964,0.8055346668446274,VPS28/H4C2,2
R-HSA-9700206,Signaling by ALK in cancer,2/206,35/3769,0.05714285714285714,1.0454923717059639,0.06500796788448185,0.5783402427067049,0.8525335253621964,0.8055346668446274,CDKN1A/BCL2A1,2
R-HSA-9725370,Signaling by ALK fusions and activated point mutants,2/206,35/3769,0.05714285714285714,1.0454923717059639,0.06500796788448185,0.5783402427067049,0.8525335253621964,0.8055346668446274,CDKN1A/BCL2A1,2
R-HSA-977443,GABA receptor activation,2/206,35/3769,0.05714285714285714,1.0454923717059639,0.06500796788448185,0.5783402427067049,0.8525335253621964,0.8055346668446274,GABRA6/KCNJ16,2
R-HSA-68886,M Phase,5/206,93/3769,0.053763440860215055,0.9836621776803424,-0.038355622677270516,0.5815028656670735,0.8525335253621964,0.8055346668446274,LMNB1/PLK4/CCNB2/TUBB6/H4C2,5
R-HSA-8939211,ESR-mediated signaling,5/206,93/3769,0.053763440860215055,0.9836621776803424,-0.038355622677270516,0.5815028656670735,0.8525335253621964,0.8055346668446274,FKBP5/CXCL12/MYC/RUNX1/H4C2,5
R-HSA-8953854,Metabolism of RNA,4/206,74/3769,0.05405405405405406,0.9889792705326687,-0.023019724738817922,0.5828249008300281,0.8525335253621964,0.8055346668446274,ZFP36/PARN/PWP2/TRMT9B,4
R-HSA-194315,Signaling by Rho GTPases,15/206,282/3769,0.05319148936170213,0.973197686428424,-0.1124998673642876,0.5854005797151034,0.8525335253621964,0.8055346668446274,SLC1A5/LMNB1/NCF2/ARAP3/TRIP10/RAC2/EPHA2/S100A8/S100A9/TAGAP/VANGL1/TUBB6/ARHGEF15/ARHGAP8/H4C2,15
R-HSA-8957275,Post-translational protein phosphorylation,3/206,55/3769,0.05454545454545454,0.9979699911738746,-0.003646191440927097,0.5861164301121862,0.8525335253621964,0.8055346668446274,SPP1/IL6/SERPINA1,3
R-HSA-157118,Signaling by NOTCH,4/206,75/3769,0.05333333333333334,0.9757928802588998,-0.05091039312777901,0.5936247375664221,0.8525335253621964,0.8055346668446274,ACTA2/MYC/RUNX1/H4C2,4
R-HSA-1912408,Pre-NOTCH Transcription and Translation,2/206,36/3769,0.05555555555555555,1.0164509169363538,0.023844790497087757,0.5938824652878298,0.8525335253621964,0.8055346668446274,RUNX1/H4C2,2
R-HSA-198725,Nuclear Events (kinase and transcription factor activation),2/206,36/3769,0.05555555555555555,1.0164509169363538,0.023844790497087757,0.5938824652878298,0.8525335253621964,0.8055346668446274,F3/EGR4,2
R-HSA-201722,Formation of the beta-catenin:TCF transactivating complex,2/206,36/3769,0.05555555555555555,1.0164509169363538,0.023844790497087757,0.5938824652878298,0.8525335253621964,0.8055346668446274,MYC/H4C2,2
R-HSA-74752,Signaling by Insulin receptor,2/206,36/3769,0.05555555555555555,1.0164509169363538,0.023844790497087757,0.5938824652878298,0.8525335253621964,0.8055346668446274,FGF20/FGF2,2
R-HSA-948021,Transport to the Golgi and subsequent modification,2/206,36/3769,0.05555555555555555,1.0164509169363538,0.023844790497087757,0.5938824652878298,0.8525335253621964,0.8055346668446274,TUBB6/SERPINA1,2
R-HSA-1251985,Nuclear signaling by ERBB4,1/206,16/3769,0.0625,1.143507281553398,0.1383011504901749,0.5938997592410806,0.8525335253621964,0.8055346668446274,CXCL12,1
R-HSA-1855204,Synthesis of IP3 and IP4 in the cytosol,1/206,16/3769,0.0625,1.143507281553398,0.1383011504901749,0.5938997592410806,0.8525335253621964,0.8055346668446274,ITPKC,1
R-HSA-2871809,FCERI mediated Ca+2 mobilization,1/206,16/3769,0.0625,1.143507281553398,0.1383011504901749,0.5938997592410806,0.8525335253621964,0.8055346668446274,FCER1G,1
R-HSA-3299685,Detoxification of Reactive Oxygen Species,1/206,16/3769,0.0625,1.143507281553398,0.1383011504901749,0.5938997592410806,0.8525335253621964,0.8055346668446274,NCF2,1
R-HSA-5620924,Intraflagellar transport,1/206,16/3769,0.0625,1.143507281553398,0.1383011504901749,0.5938997592410806,0.8525335253621964,0.8055346668446274,TUBB6,1
R-HSA-5689896,Ovarian tumor domain proteases,1/206,16/3769,0.0625,1.143507281553398,0.1383011504901749,0.5938997592410806,0.8525335253621964,0.8055346668446274,TNIP2,1
R-HSA-6802946,Signaling by moderate kinase activity BRAF mutants,1/206,16/3769,0.0625,1.143507281553398,0.1383011504901749,0.5938997592410806,0.8525335253621964,0.8055346668446274,ITGB3,1
R-HSA-6802949,Signaling by RAS mutants,1/206,16/3769,0.0625,1.143507281553398,0.1383011504901749,0.5938997592410806,0.8525335253621964,0.8055346668446274,ITGB3,1
R-HSA-6802955,Paradoxical activation of RAF signaling by kinase inactive BRAF,1/206,16/3769,0.0625,1.143507281553398,0.1383011504901749,0.5938997592410806,0.8525335253621964,0.8055346668446274,ITGB3,1
R-HSA-9634815,Transcriptional Regulation by NPAS4,1/206,16/3769,0.0625,1.143507281553398,0.1383011504901749,0.5938997592410806,0.8525335253621964,0.8055346668446274,NAMPT,1
R-HSA-9646399,Aggrephagy,1/206,16/3769,0.0625,1.143507281553398,0.1383011504901749,0.5938997592410806,0.8525335253621964,0.8055346668446274,TUBB6,1
R-HSA-9649948,Signaling downstream of RAS mutants,1/206,16/3769,0.0625,1.143507281553398,0.1383011504901749,0.5938997592410806,0.8525335253621964,0.8055346668446274,ITGB3,1
R-HSA-9656223,Signaling by RAF1 mutants,1/206,16/3769,0.0625,1.143507281553398,0.1383011504901749,0.5938997592410806,0.8525335253621964,0.8055346668446274,ITGB3,1
R-HSA-9837999,Mitochondrial protein degradation,1/206,16/3769,0.0625,1.143507281553398,0.1383011504901749,0.5938997592410806,0.8525335253621964,0.8055346668446274,PDK1,1
R-HSA-418594,G alpha (i) signalling events,8/206,152/3769,0.05263157894736842,0.962953500255493,-0.11209232222629899,0.5976000115878718,0.8563105711661633,0.8091034899381976,CXCL12/RGS16/CXCR1/CCR1/CX3CR1/FPR2/FPR1/CXCR2,8
R-HSA-196854,Metabolism of vitamins and cofactors,4/206,76/3769,0.05263157894736842,0.962953500255493,-0.07844142403429075,0.6042593900105573,0.8643067346401007,0.8166588372511104,SLC2A3/MTHFD2/NAMPT/ENPP1,4
R-HSA-3781865,Diseases of glycosylation,3/206,57/3769,0.05263157894736842,0.962953500255493,-0.06775818605568258,0.6107102045755759,0.8689585980363683,0.8210542505922187,CHSY1/THBS1/ADAMTS9,3
R-HSA-9716542,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",15/206,287/3769,0.05226480836236934,0.9562430229017963,-0.18541933649349357,0.6138060350254146,0.8689585980363683,0.8210542505922187,SLC1A5/LMNB1/NCF2/ARAP3/TRIP10/RAC2/EPHA2/S100A8/S100A9/TAGAP/VANGL1/TUBB6/ARHGEF15/ARHGAP8/H4C2,15
R-HSA-5683057,MAPK family signaling cascades,6/206,116/3769,0.05172413793103448,0.9463508536993639,-0.1411068575283693,0.6161043137760525,0.8689585980363683,0.8210542505922187,FGF20/JAK3/IL6/MYC/FGF2/ITGB3,6
R-HSA-190861,Gap junction assembly,1/206,17/3769,0.058823529411764705,1.0762421473443746,0.07574767576448409,0.6161903666475121,0.8689585980363683,0.8210542505922187,TUBB6,1
R-HSA-3214841,PKMTs methylate histone lysines,1/206,17/3769,0.058823529411764705,1.0762421473443746,0.07574767576448409,0.6161903666475121,0.8689585980363683,0.8210542505922187,H4C2,1
R-HSA-3214842,HDMs demethylate histones,1/206,17/3769,0.058823529411764705,1.0762421473443746,0.07574767576448409,0.6161903666475121,0.8689585980363683,0.8210542505922187,H4C2,1
R-HSA-445355,Smooth Muscle Contraction,1/206,17/3769,0.058823529411764705,1.0762421473443746,0.07574767576448409,0.6161903666475121,0.8689585980363683,0.8210542505922187,ACTA2,1
R-HSA-76009,Platelet Aggregation (Plug Formation),1/206,17/3769,0.058823529411764705,1.0762421473443746,0.07574767576448409,0.6161903666475121,0.8689585980363683,0.8210542505922187,ITGB3,1
R-HSA-1640170,Cell Cycle,9/206,174/3769,0.05172413793103448,0.9463508536993639,-0.1742084186131899,0.6190359720843734,0.8714372823191268,0.8233962888329748,CDK11A/LMNB1/CDK2/CDKN1A/MYC/PLK4/CCNB2/TUBB6/H4C2,9
R-HSA-9662360,Sensory processing of sound by inner hair cells of the cochlea,2/206,38/3769,0.05263157894736842,0.962953500255493,-0.05518327874678832,0.6236785635272487,0.8736017414541504,0.825441424673808,CDH23/STRC,2
R-HSA-9816359,Maternal to zygotic transition (MZT),2/206,38/3769,0.05263157894736842,0.962953500255493,-0.05518327874678832,0.6236785635272487,0.8736017414541504,0.825441424673808,TEAD4/H4C2,2
R-HSA-418555,G alpha (s) signalling events,4/206,78/3769,0.05128205128205128,0.9382623848643266,-0.13246656474791563,0.6250200313951938,0.8736017414541504,0.825441424673808,CALCA/RAMP2/GPR84/ADM,4
R-HSA-9013148,CDC42 GTPase cycle,4/206,78/3769,0.05128205128205128,0.9382623848643266,-0.13246656474791563,0.6250200313951938,0.8736017414541504,0.825441424673808,ARAP3/TAGAP/VANGL1/ARHGEF15,4
R-HSA-382551,Transport of small molecules,17/206,327/3769,0.05198776758409786,0.9511742525459458,-0.22212553654634576,0.6260267160982301,0.8736017414541504,0.825441424673808,SLC7A2/SLC38A5/SLC11A1/SLC2A3/SLC12A1/LIPG/SLC39A14/SLC1A5/LSR/ABCG2/STEAP4/SLC16A3/RUNX1/SLC13A4/ANGPTL4/SLC4A5/LCAT,17
R-HSA-195258,RHO GTPase Effectors,6/206,118/3769,0.05084745762711865,0.9303110087214087,-0.184918521138518,0.6329321752213187,0.8779817354833414,0.829579956386783,NCF2/RAC2/S100A8/S100A9/TUBB6/H4C2,6
R-HSA-2871796,FCERI mediated MAPK activation,1/206,18/3769,0.05555555555555555,1.0164509169363538,0.016820309243118396,0.6372630703976754,0.8779817354833414,0.829579956386783,FCER1G,1
R-HSA-380259,Loss of Nlp from mitotic centrosomes,1/206,18/3769,0.05555555555555555,1.0164509169363538,0.016820309243118396,0.6372630703976754,0.8779817354833414,0.829579956386783,PLK4,1
R-HSA-380284,Loss of proteins required for interphase microtubule organization from the centrosome,1/206,18/3769,0.05555555555555555,1.0164509169363538,0.016820309243118396,0.6372630703976754,0.8779817354833414,0.829579956386783,PLK4,1
R-HSA-5687128,MAPK6/MAPK4 signaling,1/206,18/3769,0.05555555555555555,1.0164509169363538,0.016820309243118396,0.6372630703976754,0.8779817354833414,0.829579956386783,MYC,1
R-HSA-9609736,Assembly and cell surface presentation of NMDA receptors,1/206,18/3769,0.05555555555555555,1.0164509169363538,0.016820309243118396,0.6372630703976754,0.8779817354833414,0.829579956386783,TUBB6,1
R-HSA-1650814,Collagen biosynthesis and modifying enzymes,2/206,39/3769,0.05128205128205128,0.9382623848643266,-0.09317703418231787,0.6379342946957611,0.8779817354833414,0.829579956386783,PLOD2/COL3A1,2
R-HSA-8939236,RUNX1 regulates transcription of genes involved in differentiation of HSCs,2/206,39/3769,0.05128205128205128,0.9382623848643266,-0.09317703418231787,0.6379342946957611,0.8779817354833414,0.829579956386783,RUNX1/H4C2,2
R-HSA-9013408,RHOG GTPase cycle,2/206,40/3769,0.05,0.9148058252427186,-0.1302341411887129,0.6517649890368562,0.8802750326701585,0.8317468276363019,EPHA2/VANGL1,2
R-HSA-9645723,Diseases of programmed cell death,2/206,40/3769,0.05,0.9148058252427186,-0.1302341411887129,0.6517649890368562,0.8802750326701585,0.8317468276363019,LMNB1/H4C2,2
R-HSA-1296041,Activation of G protein gated Potassium channels,1/206,19/3769,0.05263157894736842,0.962953500255493,-0.03892149322051568,0.6571841067874591,0.8802750326701585,0.8317468276363019,KCNJ16,1
R-HSA-1296059,G protein gated Potassium channels,1/206,19/3769,0.05263157894736842,0.962953500255493,-0.03892149322051568,0.6571841067874591,0.8802750326701585,0.8317468276363019,KCNJ16,1
R-HSA-2173789,TGF-beta receptor signaling activates SMADs,1/206,19/3769,0.05263157894736842,0.962953500255493,-0.03892149322051568,0.6571841067874591,0.8802750326701585,0.8317468276363019,ITGB3,1
R-HSA-4551638,SUMOylation of chromatin organization proteins,1/206,19/3769,0.05263157894736842,0.962953500255493,-0.03892149322051568,0.6571841067874591,0.8802750326701585,0.8317468276363019,H4C2,1
R-HSA-456926,Thrombin signalling through proteinase activated receptors (PARs),1/206,19/3769,0.05263157894736842,0.962953500255493,-0.03892149322051568,0.6571841067874591,0.8802750326701585,0.8317468276363019,F2RL3,1
R-HSA-5362517,Signaling by Retinoic Acid,1/206,19/3769,0.05263157894736842,0.962953500255493,-0.03892149322051568,0.6571841067874591,0.8802750326701585,0.8317468276363019,PDK1,1
R-HSA-69239,Synthesis of DNA,1/206,19/3769,0.05263157894736842,0.962953500255493,-0.03892149322051568,0.6571841067874591,0.8802750326701585,0.8317468276363019,CDK2,1
R-HSA-8874081,MET activates PTK2 signaling,1/206,19/3769,0.05263157894736842,0.962953500255493,-0.03892149322051568,0.6571841067874591,0.8802750326701585,0.8317468276363019,COL3A1,1
R-HSA-8955332,Carboxyterminal post-translational modifications of tubulin,1/206,19/3769,0.05263157894736842,0.962953500255493,-0.03892149322051568,0.6571841067874591,0.8802750326701585,0.8317468276363019,TUBB6,1
R-HSA-9013694,Signaling by NOTCH4,1/206,19/3769,0.05263157894736842,0.962953500255493,-0.03892149322051568,0.6571841067874591,0.8802750326701585,0.8317468276363019,ACTA2,1
R-HSA-917977,Transferrin endocytosis and recycling,1/206,19/3769,0.05263157894736842,0.962953500255493,-0.03892149322051568,0.6571841067874591,0.8802750326701585,0.8317468276363019,STEAP4,1
R-HSA-977606,Regulation of Complement cascade,1/206,19/3769,0.05263157894736842,0.962953500255493,-0.03892149322051568,0.6571841067874591,0.8802750326701585,0.8317468276363019,CR2,1
R-HSA-9821993,Replacement of protamines by nucleosomes in the male pronucleus,1/206,19/3769,0.05263157894736842,0.962953500255493,-0.03892149322051568,0.6571841067874591,0.8802750326701585,0.8317468276363019,H4C2,1
R-HSA-997272,Inhibition  of voltage gated Ca2+ channels via Gbeta/gamma subunits,1/206,19/3769,0.05263157894736842,0.962953500255493,-0.03892149322051568,0.6571841067874591,0.8802750326701585,0.8317468276363019,KCNJ16,1
R-HSA-5684996,MAPK1/MAPK3 signaling,5/206,102/3769,0.049019607843137254,0.8968684561203122,-0.2538734565946216,0.664072712552362,0.8819037741751395,0.8332857791338792,FGF20/JAK3/IL6/FGF2/ITGB3,5
R-HSA-1912422,Pre-NOTCH Expression and Processing,2/206,41/3769,0.04878048780487805,0.8924934880416766,-0.16640634971083026,0.665174288994186,0.8819037741751395,0.8332857791338792,RUNX1/H4C2,2
R-HSA-110328,Recognition and association of DNA glycosylase with site containing an affected pyrimidine,1/206,20/3769,0.05,0.9148058252427186,-0.09184347854097763,0.6760161265212681,0.8819037741751395,0.8332857791338792,H4C2,1
R-HSA-110329,Cleavage of the damaged pyrimidine,1/206,20/3769,0.05,0.9148058252427186,-0.09184347854097763,0.6760161265212681,0.8819037741751395,0.8332857791338792,H4C2,1
R-HSA-110330,Recognition and association of DNA glycosylase with site containing an affected purine,1/206,20/3769,0.05,0.9148058252427186,-0.09184347854097763,0.6760161265212681,0.8819037741751395,0.8332857791338792,H4C2,1
R-HSA-110331,Cleavage of the damaged purine,1/206,20/3769,0.05,0.9148058252427186,-0.09184347854097763,0.6760161265212681,0.8819037741751395,0.8332857791338792,H4C2,1
R-HSA-171306,Packaging Of Telomere Ends,1/206,20/3769,0.05,0.9148058252427186,-0.09184347854097763,0.6760161265212681,0.8819037741751395,0.8332857791338792,H4C2,1
R-HSA-2122947,NOTCH1 Intracellular Domain Regulates Transcription,1/206,20/3769,0.05,0.9148058252427186,-0.09184347854097763,0.6760161265212681,0.8819037741751395,0.8332857791338792,MYC,1
R-HSA-3560782,Diseases associated with glycosaminoglycan metabolism,1/206,20/3769,0.05,0.9148058252427186,-0.09184347854097763,0.6760161265212681,0.8819037741751395,0.8332857791338792,CHSY1,1
R-HSA-451927,Interleukin-2 family signaling,1/206,20/3769,0.05,0.9148058252427186,-0.09184347854097763,0.6760161265212681,0.8819037741751395,0.8332857791338792,JAK3,1
R-HSA-6811436,COPI-independent Golgi-to-ER retrograde traffic,1/206,20/3769,0.05,0.9148058252427186,-0.09184347854097763,0.6760161265212681,0.8819037741751395,0.8332857791338792,TUBB6,1
R-HSA-73927,Depurination,1/206,20/3769,0.05,0.9148058252427186,-0.09184347854097763,0.6760161265212681,0.8819037741751395,0.8332857791338792,H4C2,1
R-HSA-73928,Depyrimidination,1/206,20/3769,0.05,0.9148058252427186,-0.09184347854097763,0.6760161265212681,0.8819037741751395,0.8332857791338792,H4C2,1
R-HSA-73929,"Base-Excision Repair, AP Site Formation",1/206,20/3769,0.05,0.9148058252427186,-0.09184347854097763,0.6760161265212681,0.8819037741751395,0.8332857791338792,H4C2,1
R-HSA-8854518,AURKA Activation by TPX2,1/206,20/3769,0.05,0.9148058252427186,-0.09184347854097763,0.6760161265212681,0.8819037741751395,0.8332857791338792,PLK4,1
R-HSA-9725554,Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin,1/206,20/3769,0.05,0.9148058252427186,-0.09184347854097763,0.6760161265212681,0.8819037741751395,0.8332857791338792,ABCG2,1
R-HSA-69002,DNA Replication Pre-Initiation,2/206,42/3769,0.047619047619047616,0.8712436430883032,-0.20174128137823036,0.6781667064769841,0.8832707835578281,0.8345774273974352,CDK2/H4C2,2
R-HSA-9734767,Developmental Cell Lineages,3/206,64/3769,0.046875,0.8576304611650486,-0.2761811954800111,0.6889115632943041,0.8920522130238036,0.8428747501992438,ABCG2/FGF2/COL3A1,3
R-HSA-168142,Toll Like Receptor 10 (TLR10) Cascade,2/206,43/3769,0.046511627906976744,0.8509821630164822,-0.2362828517623742,0.6907475178616698,0.8920522130238036,0.8428747501992438,TIFA/TNIP2,2
R-HSA-168176,Toll Like Receptor 5 (TLR5) Cascade,2/206,43/3769,0.046511627906976744,0.8509821630164822,-0.2362828517623742,0.6907475178616698,0.8920522130238036,0.8428747501992438,TIFA/TNIP2,2
R-HSA-975871,MyD88 cascade initiated on plasma membrane,2/206,43/3769,0.046511627906976744,0.8509821630164822,-0.2362828517623742,0.6907475178616698,0.8920522130238036,0.8428747501992438,TIFA/TNIP2,2
R-HSA-5607764,CLEC7A (Dectin-1) signaling,1/206,21/3769,0.047619047619047616,0.8712436430883032,-0.1422524262384735,0.6938183879074027,0.8920522130238036,0.8428747501992438,IL1B,1
R-HSA-6791226,Major pathway of rRNA processing in the nucleolus and cytosol,1/206,21/3769,0.047619047619047616,0.8712436430883032,-0.1422524262384735,0.6938183879074027,0.8920522130238036,0.8428747501992438,PWP2,1
R-HSA-8868773,rRNA processing in the nucleus and cytosol,1/206,21/3769,0.047619047619047616,0.8712436430883032,-0.1422524262384735,0.6938183879074027,0.8920522130238036,0.8428747501992438,PWP2,1
R-HSA-9913351,Formation of the dystrophin-glycoprotein complex (DGC),1/206,21/3769,0.047619047619047616,0.8712436430883032,-0.1422524262384735,0.6938183879074027,0.8920522130238036,0.8428747501992438,ACTA2,1
R-HSA-9006931,Signaling by Nuclear Receptors,6/206,126/3769,0.047619047619047616,0.8712436430883032,-0.353431710916973,0.6957908021876079,0.8922072079840218,0.843021200526331,FKBP5/CXCL12/MYC/PDK1/RUNX1/H4C2,6
R-HSA-9659379,Sensory processing of sound,2/206,44/3769,0.045454545454545456,0.8316416593115622,-0.2700716405331086,0.7029226677796536,0.8922072079840218,0.843021200526331,CDH23/STRC,2
R-HSA-1483249,Inositol phosphate metabolism,1/206,22/3769,0.045454545454545456,0.8316416593115622,-0.1904080374265439,0.7106469396926415,0.8922072079840218,0.843021200526331,ITPKC,1
R-HSA-162599,Late Phase of HIV Life Cycle,1/206,22/3769,0.045454545454545456,0.8316416593115622,-0.1904080374265439,0.7106469396926415,0.8922072079840218,0.843021200526331,VPS28,1
R-HSA-166658,Complement cascade,1/206,22/3769,0.045454545454545456,0.8316416593115622,-0.1904080374265439,0.7106469396926415,0.8922072079840218,0.843021200526331,CR2,1
R-HSA-2129379,Molecules associated with elastic fibres,1/206,22/3769,0.045454545454545456,0.8316416593115622,-0.1904080374265439,0.7106469396926415,0.8922072079840218,0.843021200526331,ITGB3,1
R-HSA-2644602,Signaling by NOTCH1 PEST Domain Mutants in Cancer,1/206,22/3769,0.045454545454545456,0.8316416593115622,-0.1904080374265439,0.7106469396926415,0.8922072079840218,0.843021200526331,MYC,1
R-HSA-2644603,Signaling by NOTCH1 in Cancer,1/206,22/3769,0.045454545454545456,0.8316416593115622,-0.1904080374265439,0.7106469396926415,0.8922072079840218,0.843021200526331,MYC,1
R-HSA-2644606,Constitutive Signaling by NOTCH1 PEST Domain Mutants,1/206,22/3769,0.045454545454545456,0.8316416593115622,-0.1904080374265439,0.7106469396926415,0.8922072079840218,0.843021200526331,MYC,1
R-HSA-2894858,Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer,1/206,22/3769,0.045454545454545456,0.8316416593115622,-0.1904080374265439,0.7106469396926415,0.8922072079840218,0.843021200526331,MYC,1
R-HSA-2894862,Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants,1/206,22/3769,0.045454545454545456,0.8316416593115622,-0.1904080374265439,0.7106469396926415,0.8922072079840218,0.843021200526331,MYC,1
R-HSA-3371556,Cellular response to heat stress,1/206,22/3769,0.045454545454545456,0.8316416593115622,-0.1904080374265439,0.7106469396926415,0.8922072079840218,0.843021200526331,HSPA12B,1
R-HSA-5693571,Nonhomologous End-Joining (NHEJ),1/206,22/3769,0.045454545454545456,0.8316416593115622,-0.1904080374265439,0.7106469396926415,0.8922072079840218,0.843021200526331,H4C2,1
R-HSA-72312,rRNA processing,1/206,22/3769,0.045454545454545456,0.8316416593115622,-0.1904080374265439,0.7106469396926415,0.8922072079840218,0.843021200526331,PWP2,1
R-HSA-8875878,MET promotes cell motility,1/206,22/3769,0.045454545454545456,0.8316416593115622,-0.1904080374265439,0.7106469396926415,0.8922072079840218,0.843021200526331,COL3A1,1
R-HSA-5693532,DNA Double-Strand Break Repair,2/206,45/3769,0.044444444444444446,0.8131607335490831,-0.30314521698358377,0.7146986810519729,0.895339061638959,0.8459803999190638,CDK2/H4C2,2
R-HSA-9609690,HCMV Early Events,2/206,46/3769,0.043478260869565216,0.7954833262980161,-0.33553842718010446,0.7260825821745156,0.895339061638959,0.8459803999190638,TUBB6/H4C2,2
R-HSA-9612973,Autophagy,2/206,46/3769,0.043478260869565216,0.7954833262980161,-0.33553842718010446,0.7260825821745156,0.895339061638959,0.8459803999190638,VPS28/TUBB6,2
R-HSA-190828,Gap junction trafficking,1/206,23/3769,0.043478260869565216,0.7954833262980161,-0.23653199685978635,0.7265547940890429,0.895339061638959,0.8459803999190638,TUBB6,1
R-HSA-3214858,RMTs methylate histone arginines,1/206,23/3769,0.043478260869565216,0.7954833262980161,-0.23653199685978635,0.7265547940890429,0.895339061638959,0.8459803999190638,H4C2,1
R-HSA-6804756,Regulation of TP53 Activity through Phosphorylation,1/206,23/3769,0.043478260869565216,0.7954833262980161,-0.23653199685978635,0.7265547940890429,0.895339061638959,0.8459803999190638,CDK2,1
R-HSA-6807878,COPI-mediated anterograde transport,1/206,23/3769,0.043478260869565216,0.7954833262980161,-0.23653199685978635,0.7265547940890429,0.895339061638959,0.8459803999190638,TUBB6,1
R-HSA-73884,Base Excision Repair,1/206,23/3769,0.043478260869565216,0.7954833262980161,-0.23653199685978635,0.7265547940890429,0.895339061638959,0.8459803999190638,H4C2,1
R-HSA-8873719,RAB geranylgeranylation,1/206,23/3769,0.043478260869565216,0.7954833262980161,-0.23653199685978635,0.7265547940890429,0.895339061638959,0.8459803999190638,RAB20,1
R-HSA-8964043,Plasma lipoprotein clearance,1/206,23/3769,0.043478260869565216,0.7954833262980161,-0.23653199685978635,0.7265547940890429,0.895339061638959,0.8459803999190638,LSR,1
R-HSA-9660821,ADORA2B mediated anti-inflammatory cytokines production,1/206,23/3769,0.043478260869565216,0.7954833262980161,-0.23653199685978635,0.7265547940890429,0.895339061638959,0.8459803999190638,IL6,1
R-HSA-9670095,Inhibition of DNA recombination at telomere,1/206,23/3769,0.043478260869565216,0.7954833262980161,-0.23653199685978635,0.7265547940890429,0.895339061638959,0.8459803999190638,H4C2,1
R-HSA-2682334,EPH-Ephrin signaling,2/206,47/3769,0.0425531914893617,0.7785581491427391,-0.36728364799959445,0.7370818217979404,0.905243245814915,0.8553385816951495,EPHA2/EFNA1,2
R-HSA-9820448,Developmental Cell Lineages of the Exocrine Pancreas,2/206,47/3769,0.0425531914893617,0.7785581491427391,-0.36728364799959445,0.7370818217979404,0.905243245814915,0.8553385816951495,FGF2/COL3A1,2
R-HSA-1296065,Inwardly rectifying K+ channels,1/206,24/3769,0.041666666666666664,0.7623381877022654,-0.280814972910576,0.7415920905166076,0.905243245814915,0.8553385816951495,KCNJ16,1
R-HSA-5620912,Anchoring of the basal body to the plasma membrane,1/206,24/3769,0.041666666666666664,0.7623381877022654,-0.280814972910576,0.7415920905166076,0.905243245814915,0.8553385816951495,PLK4,1
R-HSA-606279,Deposition of new CENPA-containing nucleosomes at the centromere,1/206,24/3769,0.041666666666666664,0.7623381877022654,-0.280814972910576,0.7415920905166076,0.905243245814915,0.8553385816951495,H4C2,1
R-HSA-774815,Nucleosome assembly,1/206,24/3769,0.041666666666666664,0.7623381877022654,-0.280814972910576,0.7415920905166076,0.905243245814915,0.8553385816951495,H4C2,1
R-HSA-5668914,Diseases of metabolism,4/206,91/3769,0.04395604395604396,0.8042249013122801,-0.4545204535161028,0.7425028870167281,0.905243245814915,0.8553385816951495,CHSY1/THBS1/ADAMTS9/SFTPA2,4
R-HSA-212165,Epigenetic regulation of gene expression,3/206,70/3769,0.04285714285714286,0.784119278779473,-0.4383306714261477,0.7461198029061559,0.9074410181166803,0.8574151941992156,CD36/ANGPTL4/H4C2,3
R-HSA-1474290,Collagen formation,2/206,48/3769,0.041666666666666664,0.7623381877022654,-0.3984110124991312,0.7477042096841561,0.9074410181166803,0.8574151941992156,PLOD2/COL3A1,2
R-HSA-69306,DNA Replication,2/206,48/3769,0.041666666666666664,0.7623381877022654,-0.3984110124991312,0.7477042096841561,0.9074410181166803,0.8574151941992156,CDK2/H4C2,2
R-HSA-1793185,Chondroitin sulfate/dermatan sulfate metabolism,1/206,25/3769,0.04,0.7318446601941747,-0.3234220904834172,0.7558062505576165,0.9103771529272945,0.8601894644256848,CHSY1,1
R-HSA-427359,SIRT1 negatively regulates rRNA expression,1/206,25/3769,0.04,0.7318446601941747,-0.3234220904834172,0.7558062505576165,0.9103771529272945,0.8601894644256848,H4C2,1
R-HSA-437239,Recycling pathway of L1,1/206,25/3769,0.04,0.7318446601941747,-0.3234220904834172,0.7558062505576165,0.9103771529272945,0.8601894644256848,TUBB6,1
R-HSA-73728,RNA Polymerase I Promoter Opening,1/206,25/3769,0.04,0.7318446601941747,-0.3234220904834172,0.7558062505576165,0.9103771529272945,0.8601894644256848,H4C2,1
R-HSA-9843970,Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex,1/206,25/3769,0.04,0.7318446601941747,-0.3234220904834172,0.7558062505576165,0.9103771529272945,0.8601894644256848,H4C2,1
R-HSA-8876198,RAB GEFs exchange GTP for GDP on RABs,1/206,26/3769,0.038461538461538464,0.703696788648245,-0.36449725742020744,0.7692421245921066,0.9197292901288503,0.8690260327257289,DENND2D,1
R-HSA-913709,O-linked glycosylation of mucins,1/206,26/3769,0.038461538461538464,0.703696788648245,-0.36449725742020744,0.7692421245921066,0.9197292901288503,0.8690260327257289,GALNT5,1
R-HSA-9821002,Chromatin modifications during the maternal to zygotic transition (MZT),1/206,26/3769,0.038461538461538464,0.703696788648245,-0.36449725742020744,0.7692421245921066,0.9197292901288503,0.8690260327257289,H4C2,1
R-HSA-983168,Antigen processing: Ubiquitination & Proteasome degradation,3/206,74/3769,0.04054054054054054,0.7417344528995016,-0.539456287480516,0.7794032098988796,0.9197292901288503,0.8690260327257289,SPSB1/UBA7/SOCS3,3
R-HSA-1566948,Elastic fibre formation,1/206,27/3769,0.037037037037037035,0.6776339446242359,-0.40416661924780634,0.7819421305589851,0.9197292901288503,0.8690260327257289,ITGB3,1
R-HSA-162587,HIV Life Cycle,1/206,27/3769,0.037037037037037035,0.6776339446242359,-0.40416661924780634,0.7819421305589851,0.9197292901288503,0.8690260327257289,VPS28,1
R-HSA-2142753,Arachidonate metabolism,1/206,27/3769,0.037037037037037035,0.6776339446242359,-0.40416661924780634,0.7819421305589851,0.9197292901288503,0.8690260327257289,ALOX5AP,1
R-HSA-2299718,Condensation of Prophase Chromosomes,1/206,27/3769,0.037037037037037035,0.6776339446242359,-0.40416661924780634,0.7819421305589851,0.9197292901288503,0.8690260327257289,H4C2,1
R-HSA-427389,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,1/206,27/3769,0.037037037037037035,0.6776339446242359,-0.40416661924780634,0.7819421305589851,0.9197292901288503,0.8690260327257289,H4C2,1
R-HSA-450294,MAP kinase activation,1/206,27/3769,0.037037037037037035,0.6776339446242359,-0.40416661924780634,0.7819421305589851,0.9197292901288503,0.8690260327257289,TNIP2,1
R-HSA-5625886,Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3,1/206,27/3769,0.037037037037037035,0.6776339446242359,-0.40416661924780634,0.7819421305589851,0.9197292901288503,0.8690260327257289,H4C2,1
R-HSA-5668541,TNFR2 non-canonical NF-kB pathway,1/206,27/3769,0.037037037037037035,0.6776339446242359,-0.40416661924780634,0.7819421305589851,0.9197292901288503,0.8690260327257289,TNFRSF13C,1
R-HSA-68616,Assembly of the ORC complex at the origin of replication,1/206,27/3769,0.037037037037037035,0.6776339446242359,-0.40416661924780634,0.7819421305589851,0.9197292901288503,0.8690260327257289,H4C2,1
R-HSA-9752946,Expression and translocation of olfactory receptors,1/206,27/3769,0.037037037037037035,0.6776339446242359,-0.40416661924780634,0.7819421305589851,0.9197292901288503,0.8690260327257289,OR51E1,1
R-HSA-977444,GABA B receptor activation,1/206,27/3769,0.037037037037037035,0.6776339446242359,-0.40416661924780634,0.7819421305589851,0.9197292901288503,0.8690260327257289,KCNJ16,1
R-HSA-991365,Activation of GABAB receptors,1/206,27/3769,0.037037037037037035,0.6776339446242359,-0.40416661924780634,0.7819421305589851,0.9197292901288503,0.8690260327257289,KCNJ16,1
R-HSA-1445148,Translocation of SLC2A4 (GLUT4) to the plasma membrane,1/206,28/3769,0.03571428571428571,0.6534327323162274,-0.4425413435660899,0.7939463852636481,0.9198301842323244,0.8691213646928724,TUBB6,1
R-HSA-1980143,Signaling by NOTCH1,1/206,28/3769,0.03571428571428571,0.6534327323162274,-0.4425413435660899,0.7939463852636481,0.9198301842323244,0.8691213646928724,MYC,1
R-HSA-212300,PRC2 methylates histones and DNA,1/206,28/3769,0.03571428571428571,0.6534327323162274,-0.4425413435660899,0.7939463852636481,0.9198301842323244,0.8691213646928724,H4C2,1
R-HSA-419037,NCAM1 interactions,1/206,28/3769,0.03571428571428571,0.6534327323162274,-0.4425413435660899,0.7939463852636481,0.9198301842323244,0.8691213646928724,COL3A1,1
R-HSA-5250924,B-WICH complex positively regulates rRNA expression,1/206,28/3769,0.03571428571428571,0.6534327323162274,-0.4425413435660899,0.7939463852636481,0.9198301842323244,0.8691213646928724,H4C2,1
R-HSA-5334118,DNA methylation,1/206,28/3769,0.03571428571428571,0.6534327323162274,-0.4425413435660899,0.7939463852636481,0.9198301842323244,0.8691213646928724,H4C2,1
R-HSA-5619102,SLC transporter disorders,1/206,28/3769,0.03571428571428571,0.6534327323162274,-0.4425413435660899,0.7939463852636481,0.9198301842323244,0.8691213646928724,SLC12A1,1
R-HSA-6802952,Signaling by BRAF and RAF1 fusions,1/206,28/3769,0.03571428571428571,0.6534327323162274,-0.4425413435660899,0.7939463852636481,0.9198301842323244,0.8691213646928724,ITGB3,1
R-HSA-73772,RNA Polymerase I Promoter Escape,1/206,28/3769,0.03571428571428571,0.6534327323162274,-0.4425413435660899,0.7939463852636481,0.9198301842323244,0.8691213646928724,H4C2,1
R-HSA-9710421,Defective pyroptosis,1/206,28/3769,0.03571428571428571,0.6534327323162274,-0.4425413435660899,0.7939463852636481,0.9198301842323244,0.8691213646928724,H4C2,1
R-HSA-201681,TCF dependent signaling in response to WNT,3/206,76/3769,0.039473684210526314,0.7222151251916198,-0.5881754364226381,0.7946597846301728,0.9198301842323244,0.8691213646928724,LGR6/MYC/H4C2,3
R-HSA-5617833,Cilium Assembly,2/206,54/3769,0.037037037037037035,0.6776339446242359,-0.5736512205531995,0.8039929759071129,0.9210464250357489,0.8702705560164314,PLK4/TUBB6,2
R-HSA-375280,Amine ligand-binding receptors,1/206,29/3769,0.034482758620689655,0.6309005691329093,-0.4797198834052462,0.8052928286305789,0.9210464250357489,0.8702705560164314,HTR2B,1
R-HSA-383280,Nuclear Receptor transcription pathway,1/206,29/3769,0.034482758620689655,0.6309005691329093,-0.4797198834052462,0.8052928286305789,0.9210464250357489,0.8702705560164314,NR4A1,1
R-HSA-390466,Chaperonin-mediated protein folding,1/206,29/3769,0.034482758620689655,0.6309005691329093,-0.4797198834052462,0.8052928286305789,0.9210464250357489,0.8702705560164314,TUBB6,1
R-HSA-4086400,PCP/CE pathway,1/206,29/3769,0.034482758620689655,0.6309005691329093,-0.4797198834052462,0.8052928286305789,0.9210464250357489,0.8702705560164314,RAC2,1
R-HSA-448424,Interleukin-17 signaling,1/206,29/3769,0.034482758620689655,0.6309005691329093,-0.4797198834052462,0.8052928286305789,0.9210464250357489,0.8702705560164314,TNIP2,1
R-HSA-5693565,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,1/206,29/3769,0.034482758620689655,0.6309005691329093,-0.4797198834052462,0.8052928286305789,0.9210464250357489,0.8702705560164314,H4C2,1
R-HSA-9692914,SARS-CoV-1-host interactions,1/206,29/3769,0.034482758620689655,0.6309005691329093,-0.4797198834052462,0.8052928286305789,0.9210464250357489,0.8702705560164314,RUNX1,1
R-HSA-5673001,RAF/MAP kinase cascade,4/206,100/3769,0.04,0.7318446601941747,-0.6534219806301118,0.8060593557428963,0.9210464250357489,0.8702705560164314,FGF20/JAK3/FGF2/ITGB3,4
R-HSA-1236394,Signaling by ERBB4,1/206,30/3769,0.03333333333333333,0.6098705501618122,-0.5157898316431935,0.8160173412781996,0.9229417551942937,0.8720613995462214,CXCL12,1
R-HSA-418597,G alpha (z) signalling events,1/206,30/3769,0.03333333333333333,0.6098705501618122,-0.5157898316431935,0.8160173412781996,0.9229417551942937,0.8720613995462214,RGS16,1
R-HSA-5250913,Positive epigenetic regulation of rRNA expression,1/206,30/3769,0.03333333333333333,0.6098705501618122,-0.5157898316431935,0.8160173412781996,0.9229417551942937,0.8720613995462214,H4C2,1
R-HSA-5693606,DNA Double Strand Break Response,1/206,30/3769,0.03333333333333333,0.6098705501618122,-0.5157898316431935,0.8160173412781996,0.9229417551942937,0.8720613995462214,H4C2,1
R-HSA-983189,Kinesins,1/206,30/3769,0.03333333333333333,0.6098705501618122,-0.5157898316431935,0.8160173412781996,0.9229417551942937,0.8720613995462214,TUBB6,1
R-HSA-193648,NRAGE signals death through JNK,1/206,31/3769,0.03225806451612903,0.5901973066082055,-0.5508294515444433,0.8261538557731691,0.9229417551942937,0.8720613995462214,ARHGEF15,1
R-HSA-204998,"Cell death signalling via NRAGE, NRIF and NADE",1/206,31/3769,0.03225806451612903,0.5901973066082055,-0.5508294515444433,0.8261538557731691,0.9229417551942937,0.8720613995462214,ARHGEF15,1
R-HSA-391251,Protein folding,1/206,31/3769,0.03225806451612903,0.5901973066082055,-0.5508294515444433,0.8261538557731691,0.9229417551942937,0.8720613995462214,TUBB6,1
R-HSA-5578749,Transcriptional regulation by small RNAs,1/206,31/3769,0.03225806451612903,0.5901973066082055,-0.5508294515444433,0.8261538557731691,0.9229417551942937,0.8720613995462214,H4C2,1
R-HSA-5610787,Hedgehog 'off' state,1/206,31/3769,0.03225806451612903,0.5901973066082055,-0.5508294515444433,0.8261538557731691,0.9229417551942937,0.8720613995462214,TUBB6,1
R-HSA-69473,G2/M DNA damage checkpoint,1/206,31/3769,0.03225806451612903,0.5901973066082055,-0.5508294515444433,0.8261538557731691,0.9229417551942937,0.8720613995462214,H4C2,1
R-HSA-73854,RNA Polymerase I Promoter Clearance,1/206,31/3769,0.03225806451612903,0.5901973066082055,-0.5508294515444433,0.8261538557731691,0.9229417551942937,0.8720613995462214,H4C2,1
R-HSA-73864,RNA Polymerase I Transcription,1/206,31/3769,0.03225806451612903,0.5901973066082055,-0.5508294515444433,0.8261538557731691,0.9229417551942937,0.8720613995462214,H4C2,1
R-HSA-8948216,Collagen chain trimerization,1/206,31/3769,0.03225806451612903,0.5901973066082055,-0.5508294515444433,0.8261538557731691,0.9229417551942937,0.8720613995462214,COL3A1,1
R-HSA-9648025,EML4 and NUDC in mitotic spindle formation,1/206,31/3769,0.03225806451612903,0.5901973066082055,-0.5508294515444433,0.8261538557731691,0.9229417551942937,0.8720613995462214,TUBB6,1
R-HSA-9843940,Regulation of endogenous retroelements by KRAB-ZFP proteins,1/206,31/3769,0.03225806451612903,0.5901973066082055,-0.5508294515444433,0.8261538557731691,0.9229417551942937,0.8720613995462214,H4C2,1
R-HSA-427413,NoRC negatively regulates rRNA expression,1/206,32/3769,0.03125,0.571753640776699,-0.584908948625783,0.8357344619023095,0.9297545888663193,0.8784986522043282,H4C2,1
R-HSA-5250941,Negative epigenetic regulation of rRNA expression,1/206,32/3769,0.03125,0.571753640776699,-0.584908948625783,0.8357344619023095,0.9297545888663193,0.8784986522043282,H4C2,1
R-HSA-9925563,Developmental Lineage of Pancreatic Ductal Cells,1/206,32/3769,0.03125,0.571753640776699,-0.584908948625783,0.8357344619023095,0.9297545888663193,0.8784986522043282,COL3A1,1
R-HSA-381753,Olfactory Signaling Pathway,1/206,33/3769,0.030303030303030304,0.5544277728743748,-0.6180915343050739,0.8447895062823267,0.9346359040499223,0.8831108680095856,OR51E1,1
R-HSA-6802957,Oncogenic MAPK signaling,1/206,33/3769,0.030303030303030304,0.5544277728743748,-0.6180915343050739,0.8447895062823267,0.9346359040499223,0.8831108680095856,ITGB3,1
R-HSA-9663891,Selective autophagy,1/206,33/3769,0.030303030303030304,0.5544277728743748,-0.6180915343050739,0.8447895062823267,0.9346359040499223,0.8831108680095856,TUBB6,1
R-HSA-9845323,Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs),1/206,33/3769,0.030303030303030304,0.5544277728743748,-0.6180915343050739,0.8447895062823267,0.9346359040499223,0.8831108680095856,H4C2,1
R-HSA-195721,Signaling by WNT,5/206,130/3769,0.038461538461538464,0.703696788648245,-0.8266052377522533,0.8485885375926704,0.9363445164040609,0.8847252871995793,RAC2/LGR6/MYC/WNT7A/H4C2,5
R-HSA-8978868,Fatty acid metabolism,2/206,60/3769,0.03333333333333333,0.6098705501618122,-0.7323810352730153,0.8488846586291243,0.9363445164040609,0.8847252871995793,ALOX5AP/ACSL5,2
R-HSA-168255,Influenza Infection,1/206,34/3769,0.029411764705882353,0.5381210736721873,-0.6504343207199642,0.8533476866104426,0.9363445164040609,0.8847252871995793,ISG15,1
R-HSA-2022090,Assembly of collagen fibrils and other multimeric structures,1/206,34/3769,0.029411764705882353,0.5381210736721873,-0.6504343207199642,0.8533476866104426,0.9363445164040609,0.8847252871995793,COL3A1,1
R-HSA-3214815,HDACs deacetylate histones,1/206,34/3769,0.029411764705882353,0.5381210736721873,-0.6504343207199642,0.8533476866104426,0.9363445164040609,0.8847252871995793,H4C2,1
R-HSA-6811434,COPI-dependent Golgi-to-ER retrograde traffic,1/206,34/3769,0.029411764705882353,0.5381210736721873,-0.6504343207199642,0.8533476866104426,0.9363445164040609,0.8847252871995793,TUBB6,1
R-HSA-1442490,Collagen degradation,1/206,35/3769,0.02857142857142857,0.5227461858529819,-0.681989077714946,0.8614361408429054,0.9371433989569367,0.8854801285893126,COL3A1,1
R-HSA-375165,NCAM signaling for neurite out-growth,1/206,35/3769,0.02857142857142857,0.5227461858529819,-0.681989077714946,0.8614361408429054,0.9371433989569367,0.8854801285893126,COL3A1,1
R-HSA-5617472,Activation of anterior HOX genes in hindbrain development during early embryogenesis,1/206,35/3769,0.02857142857142857,0.5227461858529819,-0.681989077714946,0.8614361408429054,0.9371433989569367,0.8854801285893126,H4C2,1
R-HSA-5619507,Activation of HOX genes during differentiation,1/206,35/3769,0.02857142857142857,0.5227461858529819,-0.681989077714946,0.8614361408429054,0.9371433989569367,0.8854801285893126,H4C2,1
R-HSA-6806834,Signaling by MET,1/206,35/3769,0.02857142857142857,0.5227461858529819,-0.681989077714946,0.8614361408429054,0.9371433989569367,0.8854801285893126,COL3A1,1
R-HSA-446203,Asparagine N-linked glycosylation,2/206,63/3769,0.031746031746031744,0.5808290953922022,-0.8066587390933665,0.8676487824697425,0.9371433989569367,0.8854801285893126,TUBB6/SERPINA1,2
R-HSA-163125,Post-translational modification: synthesis of GPI-anchored proteins,1/206,36/3769,0.027777777777777776,0.5082254584681769,-0.7128028765809777,0.8690805315730503,0.9371433989569367,0.8854801285893126,PLAUR,1
R-HSA-2454202,Fc epsilon receptor (FCERI) signaling,1/206,36/3769,0.027777777777777776,0.5082254584681769,-0.7128028765809777,0.8690805315730503,0.9371433989569367,0.8854801285893126,FCER1G,1
R-HSA-2467813,Separation of Sister Chromatids,1/206,36/3769,0.027777777777777776,0.5082254584681769,-0.7128028765809777,0.8690805315730503,0.9371433989569367,0.8854801285893126,TUBB6,1
R-HSA-5625740,RHO GTPases activate PKNs,1/206,36/3769,0.027777777777777776,0.5082254584681769,-0.7128028765809777,0.8690805315730503,0.9371433989569367,0.8854801285893126,H4C2,1
R-HSA-68867,Assembly of the pre-replicative complex,1/206,36/3769,0.027777777777777776,0.5082254584681769,-0.7128028765809777,0.8690805315730503,0.9371433989569367,0.8854801285893126,H4C2,1
R-HSA-187037,Signaling by NTRK1 (TRKA),2/206,64/3769,0.03125,0.571753640776699,-0.8307506817688557,0.8734144992173373,0.9371433989569367,0.8854801285893126,F3/EGR4,2
R-HSA-373760,L1CAM interactions,2/206,64/3769,0.03125,0.571753640776699,-0.8307506817688557,0.8734144992173373,0.9371433989569367,0.8854801285893126,TUBB6/ITGB3,2
R-HSA-193704,p75 NTR receptor-mediated signalling,1/206,37/3769,0.02702702702702703,0.4944896352663343,-0.7429186401856186,0.8763051258660993,0.9371433989569367,0.8854801285893126,ARHGEF15,1
R-HSA-3214847,HATs acetylate histones,1/206,37/3769,0.02702702702702703,0.4944896352663343,-0.7429186401856186,0.8763051258660993,0.9371433989569367,0.8854801285893126,H4C2,1
R-HSA-428157,Sphingolipid metabolism,1/206,37/3769,0.02702702702702703,0.4944896352663343,-0.7429186401856186,0.8763051258660993,0.9371433989569367,0.8854801285893126,ABCG2,1
R-HSA-9007101,Rab regulation of trafficking,1/206,37/3769,0.02702702702702703,0.4944896352663343,-0.7429186401856186,0.8763051258660993,0.9371433989569367,0.8854801285893126,DENND2D,1
R-HSA-9013106,RHOC GTPase cycle,1/206,37/3769,0.02702702702702703,0.4944896352663343,-0.7429186401856186,0.8763051258660993,0.9371433989569367,0.8854801285893126,VANGL1,1
R-HSA-9842860,Regulation of endogenous retroelements,1/206,37/3769,0.02702702702702703,0.4944896352663343,-0.7429186401856186,0.8763051258660993,0.9371433989569367,0.8854801285893126,H4C2,1
R-HSA-2980736,Peptide hormone metabolism,1/206,38/3769,0.02631578947368421,0.4814767501277465,-0.7723756152869433,0.88313287079417635,0.9394281932352393,0.8876389656825509,INHBB,1
R-HSA-438064,Post NMDA receptor activation events,1/206,38/3769,0.02631578947368421,0.4814767501277465,-0.7723756152869433,0.88313287079417635,0.9394281932352393,0.8876389656825509,TUBB6,1
R-HSA-5663220,RHO GTPases Activate Formins,1/206,38/3769,0.02631578947368421,0.4814767501277465,-0.7723756152869433,0.88313287079417635,0.9394281932352393,0.8876389656825509,TUBB6,1
R-HSA-9013026,RHOB GTPase cycle,1/206,38/3769,0.02631578947368421,0.4814767501277465,-0.7723756152869433,0.88313287079417635,0.9394281932352393,0.8876389656825509,VANGL1,1
R-HSA-1632852,Macroautophagy,1/206,40/3769,0.025,0.4574029126213593,-0.8294541955195657,0.8956834258216493,0.9477442854466858,0.8954966045550523,TUBB6,1
R-HSA-211000,Gene Silencing by RNA,1/206,40/3769,0.025,0.4574029126213593,-0.8294541955195657,0.8956834258216493,0.9477442854466858,0.8954966045550523,H4C2,1
R-HSA-9678108,SARS-CoV-1 Infection,1/206,40/3769,0.025,0.4574029126213593,-0.8294541955195657,0.8956834258216493,0.9477442854466858,0.8954966045550523,RUNX1,1
R-HSA-9748784,Drug ADME,1/206,40/3769,0.025,0.4574029126213593,-0.8294541955195657,0.8956834258216493,0.9477442854466858,0.8954966045550523,ABCG2,1
R-HSA-5689880,Ub-specific processing proteases,1/206,41/3769,0.024390243902439025,0.4462467440208383,-0.8571393145347506,0.9014461542423358,0.9525836009869537,0.9000691360925419,MYC,1
R-HSA-5633007,Regulation of TP53 Activity,1/206,42/3769,0.023809523809523808,0.4356218215441516,-0.8842932468311477,0.9068919944317346,0.9554487541022505,0.9027763377350918,CDK2,1
R-HSA-166520,Signaling by NTRKs,2/206,71/3769,0.028169014084507043,0.5153835635170244,-0.991117185833523,0.9077359573930245,0.9554487541022505,0.9027763377350918,F3/EGR4,2
R-HSA-5688426,Deubiquitination,2/206,71/3769,0.028169014084507043,0.5153835635170244,-0.991117185833523,0.9077359573930245,0.9554487541022505,0.9027763377350918,MYC/TNIP2,2
R-HSA-1428517,Aerobic respiration and respiratory electron transport,1/206,43/3769,0.023255813953488372,0.4254910815082411,-0.9109419944081232,0.9120382914929267,0.9573810375196008,0.904602097347517,PDK1,1
R-HSA-5358351,Signaling by Hedgehog,1/206,43/3769,0.023255813953488372,0.4254910815082411,-0.9109419944081232,0.9120382914929267,0.9573810375196008,0.904602097347517,TUBB6,1
R-HSA-1266738,Developmental Biology,24/206,551/3769,0.043557168784029036,0.7969270346942011,-1.2402694206359066,0.9133694032925176,0.9573810375196008,0.904602097347517,ZIC2/EDN1/CXCL12/ABCG2/CDK2/EDN3/CDKN1A/DSC2/CD36/MYC/FGF2/BCL2A1/EPHA2/PLAC8/RUNX1/ANGPTL4/COL3A1/EFNA1/TUBB6/TEAD4/SPINK9/CRIPTO/ITGB3/H4C2,24
R-HSA-5653656,Vesicle-mediated transport,8/206,216/3769,0.037037037037037035,0.6776339446242359,-1.173166688587112,0.9143526762827647,0.9573810375196008,0.904602097347517,TJP1/TRIP10/CD36/VPS28/DENND2D/COL3A1/TUBB6/SERPINA1,8
R-HSA-2559580,Oxidative Stress Induced Senescence,1/206,44/3769,0.022727272727272728,0.4158208296557811,-0.9371096570267431,0.9169014455327702,0.9575463596763348,0.9047583055487021,H4C2,1
R-HSA-442755,Activation of NMDA receptors and postsynaptic events,1/206,44/3769,0.022727272727272728,0.4158208296557811,-0.9371096570267431,0.9169014455327702,0.9575463596763348,0.9047583055487021,TUBB6,1
R-HSA-422356,Regulation of insulin secretion,1/206,45/3769,0.022222222222222223,0.40658036677454157,-0.9628186135258051,0.9214969629073337,0.9598427402974958,0.9069280902475847,CD36,1
R-HSA-5619115,Disorders of transmembrane transporters,1/206,45/3769,0.022222222222222223,0.40658036677454157,-0.9628186135258051,0.9214969629073337,0.9598427402974958,0.9069280902475847,SLC12A1,1
R-HSA-416482,G alpha (12/13) signalling events,1/206,46/3769,0.021739130434782608,0.39774166314900805,-0.9880896821036408,0.9258395047013964,0.9618643881528127,0.9088382877743247,ARHGEF15,1
R-HSA-8856688,Golgi-to-ER retrograde transport,1/206,46/3769,0.021739130434782608,0.39774166314900805,-0.9880896821036408,0.9258395047013964,0.9618643881528127,0.9088382877743247,TUBB6,1
R-HSA-2132295,MHC class II antigen presentation,1/206,49/3769,0.02040816326530612,0.37339013275212996,-1.0614632084065265,0.9374841542804586,0.9727005279516157,0.9190770478969864,TUBB6,1
R-HSA-376176,Signaling by ROBO receptors,1/206,50/3769,0.02,0.36592233009708736,-1.0851643507604765,0.9409460532638525,0.9746364903746737,0.920906283697208,CXCL12,1
R-HSA-1852241,Organelle biogenesis and maintenance,2/206,81/3769,0.024691358024691357,0.4517559630828239,-1.1992289829904368,0.9419785335254883,0.9746364903746737,0.920906283697208,PLK4/TUBB6,2
R-HSA-112314,Neurotransmitter receptors and postsynaptic signal transmission,3/206,109/3769,0.027522935779816515,0.5035628395831478,-1.2644979661796851,0.9435968347200541,0.9746364903746737,0.920906283697208,GABRA6/KCNJ16/TUBB6,3
R-HSA-3108232,SUMO E3 ligases SUMOylate target proteins,1/206,51/3769,0.0196078431372549,0.3587473824481249,-1.1085127489694926,0.9442171242581108,0.9746364903746737,0.920906283697208,H4C2,1
R-HSA-1483206,Glycerophospholipid biosynthesis,1/206,52/3769,0.019230769230769232,0.3518483943241225,-1.1315223551225158,0.9473078376531697,0.9753130822110397,0.9215455760690421,PLA2G5,1
R-HSA-2990846,SUMOylation,1/206,52/3769,0.019230769230769232,0.3518483943241225,-1.1315223551225158,0.9473078376531697,0.9753130822110397,0.9215455760690421,H4C2,1
R-HSA-6811442,Intra-Golgi and retrograde Golgi-to-ER traffic,1/206,54/3769,0.018518518518518517,0.33881697231211794,-1.1765768898964815,0.9529872451437724,0.9799008772274219,0.925880453021245,TUBB6,1
R-HSA-163685,Integration of energy metabolism,1/206,55/3769,0.01818181818181818,0.33265666372462493,-1.1986458036891396,0.9555941435288016,0.9800651843361972,0.9260357021325,CD36,1
R-HSA-3247509,Chromatin modifying enzymes,1/206,55/3769,0.01818181818181818,0.33265666372462493,-1.1986458036891396,0.9555941435288016,0.9800651843361972,0.9260357021325,H4C2,1
R-HSA-3858494,Beta-catenin independent WNT signaling,1/206,56/3769,0.017857142857142856,0.3267163661581137,-1.2204240088646203,0.958057150107441,0.9813347534987983,0.9272352819050345,RAC2,1
R-HSA-4839726,Chromatin organization,1/206,58/3769,0.017241379310344827,0.31545028456645463,-1.2631492249565472,0.9625826783710154,0.9847110158048318,0.9304254160768436,H4C2,1
R-HSA-199991,Membrane Trafficking,6/206,200/3769,0.03,0.5488834951456311,-1.5762009564560917,0.9680848289517554,0.9881032456271572,0.9336306375003958,TJP1/TRIP10/VPS28/DENND2D/TUBB6/SERPINA1,6
R-HSA-8856828,Clathrin-mediated endocytosis,1/206,61/3769,0.01639344262295082,0.29993633614515364,-1.3252985946116314,0.9684758593256874,0.9881032456271572,0.9336306375003958,TRIP10,1
R-HSA-597592,Post-translational protein modification,16/206,430/3769,0.037209302325581395,0.6807857304131858,-1.690789185534294,0.9695994395292704,0.9881032456271572,0.9336306375003958,PLAUR/CISH/SPP1/CDKN1A/IL6/GALNT5/MYC/THBS1/RAB20/ADAMTS9/TNIP2/SPSB1/TUBB6/SOCS3/SERPINA1/H4C2,16
R-HSA-1630316,Glycosaminoglycan metabolism,1/206,66/3769,0.015151515151515152,0.2772138864371874,-1.424249441928339,0.9763159273537348,0.9936836820970034,0.9389034331135364,CHSY1,1
R-HSA-392499,Metabolism of proteins,22/206,572/3769,0.038461538461538464,0.703696788648245,-1.8498827418826456,0.9782755487474384,0.9944146123689063,0.9395940683267543,PLAUR/CALCA/CISH/SPP1/CDKN1A/IL6/GALNT5/MYC/THBS1/RAB20/PDK1/INHBB/ADAMTS9/B2M/TNIP2/SPSB1/TUBB6/PAPPA/SOCS3/SFTPA2/SERPINA1/H4C2,22
R-HSA-1296071,Potassium Channels,1/206,71/3769,0.014084507042253521,0.2576917817585122,-1.5181375968671782,0.98221324019945,0.9964222186230838,0.9414909983441714,KCNJ16,1
R-HSA-9709957,Sensory Perception,3/206,138/3769,0.021739130434782608,0.39774166314900805,-1.732967369365987,0.9840319674440745,0.9964222186230838,0.9414909983441714,CDH23/OR51E1/STRC,3
R-HSA-397014,Muscle contraction,2/206,109/3769,0.01834862385321101,0.3357085597220985,-1.692047336820327,0.9850626576577187,0.9964222186230838,0.9414909983441714,ACTA2/KCNE4,2
R-HSA-556833,Metabolism of lipids,8/206,271/3769,0.02952029520295203,0.5401067602909039,-1.8893521604559087,0.9852264633576557,0.9964222186230838,0.9414909983441714,ABCG2/G0S2/PLA2G5/ALOX5AP/CD36/HILPDA/ANGPTL4/ACSL5,8
R-HSA-71387,Metabolism of carbohydrates and carbohydrate derivatives,2/206,112/3769,0.017857142857142856,0.3267163661581137,-1.739104724925667,0.9871370236833954,0.9968641384328073,0.9419085557962921,PYGL/CHSY1,2
R-HSA-5576891,Cardiac conduction,1/206,80/3769,0.0125,0.22870145631067965,-1.6764643527678,0.9893876151606686,0.9968641384328073,0.9419085557962921,KCNE4,1
R-HSA-112315,Transmission across Chemical Synapses,3/206,147/3769,0.02040816326530612,0.37339013275212996,-1.863214348027819,0.9893969913284417,0.9968641384328073,0.9419085557962921,GABRA6/KCNJ16/TUBB6,3
R-HSA-422475,Axon guidance,6/206,234/3769,0.02564102564102564,0.4691311924321633,-2.0159584360543703,0.9910267384424072,0.997017869882081,0.9420538122678443,CXCL12/EPHA2/COL3A1/EFNA1/TUBB6/ITGB3,6
R-HSA-1483257,Phospholipid metabolism,1/206,85/3769,0.011764705882352941,0.21524842946887493,-1.7593935345916294,0.9920390041148796,0.997017869882081,0.9420538122678443,PLA2G5,1
R-HSA-9675108,Nervous system development,6/206,249/3769,0.024096385542168676,0.4408702772254065,-2.1949370401999353,0.9950491323047066,0.9987899185163783,0.9437281705937001,CXCL12/EPHA2/COL3A1/EFNA1/TUBB6/ITGB3,6
R-HSA-71291,Metabolism of amino acids and derivatives,1/206,108/3769,0.009259259259259259,0.16940848615605897,-2.105623160794082,0.9978893199152769,0.9999991978187497,0.9448707841930233,HDC,1
R-HSA-112316,Neuronal System,3/206,235/3769,0.01276595744680851,0.2335674447428217,-2.9171297630436634,0.9998579658016324,0.9999991978187497,0.9448707841930233,GABRA6/KCNJ16/TUBB6,3
R-HSA-1430728,Metabolism,17/206,747/3769,0.022757697456492636,0.4163774840462172,-4.28278482757046,0.9999991978187497,0.9999991978187497,0.9448707841930233,SLC2A3/MTHFD2/ITPKC/PYGL/NAMPT/ABCG2/G0S2/PLA2G5/CHSY1/ALOX5AP/CD36/HILPDA/HDC/PDK1/ANGPTL4/ACSL5/ENPP1,17
